View Filing Data

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2017
Document And Entity Information
Entity Registrant Name	OPGEN INC
Entity Central Index Key	0001293818
Document Type	S-1/A
Document Period End Date	Sep. 30, 2017
Amendment Flag	true
Amendment Description	To amend original S-1
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Trading Symbol	OPGN

Consolidated Balance Sheets - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 4,854,031	$ 4,117,324	$ 7,814,220
Accounts receivable, net	469,954	542,420	678,646
Inventory, net	461,129	692,368	826,012
Prepaid expenses and other current assets	340,923	329,646	566,239
Total current assets	6,126,037	5,681,758	9,885,117
Property and equipment, net	750,090	800,723	1,074,710
Goodwill	600,814	600,814	637,528
Intangible assets, net	1,420,136	1,620,998	1,888,814
Other noncurrent assets	321,592	279,752	270,327
Total assets	9,218,669	8,984,045	13,756,496
Current liabilities
Accounts payable	1,939,175	2,232,563	2,285,792
Accrued compensation and benefits	902,892	578,480	1,081,270
Accrued liabilities	857,024	1,215,283	920,286
Deferred revenue	31,239	37,397	50,925
Short-term notes payable	1,100,012	1,023,815	0
Current maturities of long-term capital lease obligation	160,485	184,399	251,800
Total current liabilities	4,990,827	5,271,937	4,590,073
Deferred rent	319,273	398,084	352,985
Note payable	0	0	993,750
Warrant liability	28,378	0	0
Long-term capital lease obligation and other noncurrent liabilities	119,764	146,543	328,642
Total liabilities	5,458,242	5,816,564	6,265,450
Stockholders' equity
Common stock	20,786	10,122	5,019
Preferred stock	0	0	0
Additional paid-in capital	149,493,056	136,442,302	121,611,452
Accumulated other comprehensive (loss)/income	(7,649)	6,176	(1,059)
Accumulated deficit	(145,745,766)	(133,291,119)	(114,124,366)
Total stockholders’ equity	3,760,427	3,167,481	7,491,046
Total liabilities and stockholders’ equity	$ 9,218,669	$ 8,984,045	$ 13,756,496

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000	200,000,000
Common stock, shares issued	2,078,595	1,012,170	501,907
Common stock, shares outstanding	2,078,595	1,012,170	501,907
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Revenue
Product sales	$ 729,742	$ 730,325	$ 2,145,371	$ 2,705,690	$ 3,524,178	$ 2,701,142
Laboratory services	9,070	23,036	41,025	182,130	228,904	120,476
Collaboration revenue	6,302	6,302	33,699	131,302	272,603	336,102
Total revenue	745,114	759,663	2,220,095	3,019,122	4,025,685	3,157,720
Operating expenses
Cost of products sold	448,407	400,001	1,266,148	1,269,990	1,658,571	1,179,771
Cost of services	49,119	51,802	228,115	528,733	631,333	367,802
Research and development	1,513,157	2,178,818	5,397,906	6,278,829	8,613,236	6,002,941
General and administrative	1,600,577	1,639,996	5,319,811	4,955,096	6,602,608	5,834,642
Sales and marketing	330,305	1,294,640	2,345,293	4,282,628	5,529,274	4,305,444
Transaction expenses					0	526,283
Total operating expenses	3,941,565	5,565,257	14,557,273	17,315,276	23,035,022	18,216,883
Operating loss	(3,196,451)	(4,805,594)	(12,337,178)	(14,296,154)	(19,009,337)	(15,059,163)
Other expense
Interest and other (expense)/income					(5,967)	26,657
Other (expense)/income	(87,292)	623	(87,270)	(3,078)
Interest expense	(90,317)	(41,423)	(173,974)	(109,806)	(143,347)	(1,801,320)
Foreign currency transaction gains/(losses)	8,018	(1,269)	19,636	2,293	(8,102)	0
Change in fair value of derivative financial instruments	97,395	0	124,139	0	0	(647,342)
Total other expense	(72,196)	(42,069)	(117,469)	(110,591)	(157,416)	(2,422,005)
Loss before income taxes	(3,268,647)	(4,847,663)	(12,454,647)	(14,406,745)	(19,166,753)	(17,481,168)
Provision for income taxes	0	0	0	0	0	(129,095)
Net loss	(3,268,647)	(4,847,663)	(12,454,647)	(14,406,745)	(19,166,753)	(17,352,073)
Preferred stock dividends and beneficial conversion	0	0	0	(332,550)	(332,500)	(243,762)
Net loss available to common stockholders	$ (3,268,647)	$ (4,847,663)	$ (12,454,647)	$ (14,739,295)	$ (19,499,303)	$ (17,595,835)
Net loss per common share - basic and diluted	$ (1.75)	$ (5.75)	$ (9.25)	$ (23.00)	$ (27.50)	$ (55.00)
Weighted average shares outstanding - basic and diluted	1,883,136	837,548	1,358,259	641,121	706,702	319,239
Net loss	$ (3,268,647)	$ (4,847,663)	$ (12,454,647)	$ (14,406,745)	$ (19,166,753)	$ (17,352,073)
Other comprehensive income/(loss) - foreign currency translation	(6,234)	672	(13,825)	1,059	7,235	(1,059)
Comprehensive loss	$ (3,274,881)	$ (4,846,991)	$ (12,468,472)	$ (14,405,686)	$ (19,159,518)	$ (17,353,132)

Statement - Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Preferred Stock	Additional Paid-In Capital	Accumulated Other Comprehensive (Loss)/Income	Accumulated Deficit	Total
Balance at Dec. 31, 2014	$ 197	$ 0	$ 88,706,472	$ 0	$ (96,772,293)	$ (8,065,624)
Balance (in shares) at Dec. 31, 2014	19,729	0
Stock option exercises	$ 5		2,298			$ 2,303
Stock option exercises (in shares)	458					458
Beneficial conversion feature			1,427,667			$ 1,427,667
Reclassification of warrant liability to equity			719,675			719,675
Conversion of preferred stock into common shares	$ 2,950		7,801,222			7,804,172
Conversion of preferred stock into common shares (in shares)	294,994
Demand notes tendered for IPO Units	$ 140		2,099,860			2,100,000
Demand notes tendered for IPO Units (in shares)	14,000
Issuance of units, net of offering costs	$ 1,000		12,128,133
Issuance of units, net of offering costs (in shares)	100,000
Additional IPO issuance costs			(58,566)			(58,566)
Common shares issued in business combination	$ 273		2,583,817			2,584,090
Common shares issued in business combination (in shares)	27,272
Common shares issued in financing	$ 455		4,999,547			5,000,002
Common shares issued in financing (in shares)	45,454
Stock compensation expense			1,445,088			1,445,088
Accretion of Series A preferred stock			(243,762)			(243,762)
Foreign currency translation				(1,059)		(1,059)
Net loss					(17,352,073)	(17,352,073)
Balance at Dec. 31, 2015	$ 5,019	$ 0	121,611,452	(1,059)	(114,124,366)	7,491,046
Balance (in shares) at Dec. 31, 2015	501,907	0
Stock option exercises	$ 27		23,744			$ 23,771
Stock option exercises (in shares)	2,660					2,660
Private offering of common stock, preferred stock and warrants, net of issuance costs	$ 2,698	$ 23,094	9,434,957			$ 9,460,749
Private offering of common stock, preferred stock and warrants, net of issuance costs (in shares)	269,765	2,309,428
Conversion of preferred stock into common shares	$ 924	$ (23,094)	22,170			0
Conversion of preferred stock into common shares (in shares)	92,377	(2,309,428)
Issuance of units, net of offering costs	$ 1,448		4,404,525			4,405,973
Issuance of units, net of offering costs (in shares)	144,794
Common shares issued in business combination						0
Issuance of RSUs	$ 7		(8)			(1)
Issuance of RSUs (in shares)	666
Stock compensation expense			945,461			945,461
Foreign currency translation				7,235		7,235
Net loss					(19,166,753)	(19,166,753)
Balance at Dec. 31, 2016	$ 10,122	$ 0	$ 136,442,302	$ 6,176	$ (133,291,119)	3,167,481
Balance (in shares) at Dec. 31, 2016	1,012,170	0
Net loss						(12,454,647)
Balance at Sep. 30, 2017						$ 3,760,427

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net loss	$ (12,454,647)	$ (14,406,745)	$ (19,166,753)	$ (17,352,073)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	499,651	494,828	656,047	624,653
Loss on disposal of property and equipment	0	6,308	6,309	0
Deferred tax benefit	0	0	0	(129,095)
Noncash interest expense	65,511	3,126	4,527	1,598,312
Share-based compensation	722,304	706,648	945,461	1,445,088
Inventory obsolescence	0	109,367	113,465	0
Change in fair value of derivative financial instruments	(124,139)	0	0	647,342
Unamortized discount on bridge loan at repayment	85,932	0	0	0
Other non-cash items	0	0	0	24,010
Changes in operating assets and liabilities, net of effects of acquisition:
Accounts receivable	72,466	231,960	136,226	359,298
Inventory	231,239	(113,560)	20,179	424,505
Other assets	(337,999)	124,133	263,882	(319,305)
Accounts payable	(293,388)	(349,780)	(53,229)	196,444
Accrued compensation and other liabilities	337,562	313,644	(163,223)	(1,508,937)
Deferred revenue	(6,158)	13,499	(13,528)	(288,246)
Net cash used in operating activities	(11,201,666)	(12,866,572)	(17,250,637)	(14,278,004)
Cash flows from investing activities
Cash acquired in business combinations			0	1,367,211
Purchases of property and equipment (net of proceeds on disposals)	(142,687)	(87,533)	(123,514)	(185,296)
Net cash (used in)/provided by investing activities	(142,687)	(87,533)	(123,514)	1,181,915
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	3,426,050	124	4,405,973	17,366,620
Proceeds from issuance of convertible notes and warrants, net of issuance costs			0	1,388,815
Proceeds from issuance of promissory notes, net of issuance costs	0	204,895	204,895	1,741,667
Proceeds from issuance of units, net of selling costs	8,754,882	0
Proceeds from exercise of stock options and warrants	48,179	23,771	23,771	2,293
Proceeds from private offering of common stock, preferred stock and warrants, net of issuance costs	0	9,460,751	9,460,749	0
Proceeds from debt, net of issuance costs	1,168,222	0
Payments on debt	(1,146,287)	(101,796)	(178,997)	(155,000)
Payments on capital lease obligations	(156,161)	(188,231)	(251,701)	(175,317)
Net cash provided by financing activities	12,094,885	9,399,514	13,664,690	20,169,078
Effects of exchange rates on cash	(13,825)	1,276	12,565	(8,286)
Net (decrease)/increase in cash and cash equivalents	736,707	(3,553,315)	(3,696,896)	7,064,703
Cash and cash equivalents at beginning of period	4,117,324	7,814,220	7,814,220	749,517
Cash and cash equivalents at end of period	4,854,031	4,260,905	4,117,324	7,814,220
Supplemental disclosure of cash flow information
Cash paid for interest	108,463	46,022	58,564	194,288
Supplemental disclosures of noncash investing and financing activities:
Acquisition of equipment purchased through capital leases			0	580,477
Common stock issued in business combination			0	2,584,090
Conversion of convertible promissory notes to Series A preferred stock			0	3,000,000
Conversion of series A preferred stock into common shares			0	8,183,661
Exchange of demand notes for IPO units			0	2,100,000
Exchange of demand note for convertible debt			$ 0	$ 300,000
Unpaid deferred offering costs	0	137,178
Shares issued to settle obligations	110,000	0
Issuance of placement agent warrant	$ 93,677	$ 0

Organization

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

OpGen, Inc. ("OpGen" or the "Company") was incorporated in Delaware in 2001. References in this report to the "Company" include OpGen and its wholly-owned subsidiaries. The Company's headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark. The Company operates in one business segment.

OpGen is a precision medicine company using molecular diagnostics and informatics to help combat infectious disease. The Company is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections.

The Company's molecular diagnostics and informatics offerings combine its Acuitas DNA tests and Acuitas Lighthouse informatics platform for use with its proprietary, curated MDRO knowledgebase. The Company is working to deliver our products and services, some in development, to a global network of customers and partners. These include:

Its Acuitas DNA tests provide rapid microbial identification and antibiotic resistance gene information. These products include our Acuitas Rapid Test for complicated urinary tract infection in development, the QuickFISH family of FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures, and its Acuitas Resistome Tests for genetic analysis of hospital surveillance isolates.

Its Acuitas Lighthouse informatics systems are cloud-based HIPAA compliant informatics offerings that combine clinical lab test results with patient and hospital information to provide analytics and actionable insights to help manage MDROs in the hospital and patient care environment. Components of its informatics systems are the Acuitas Lighthouse Knowledgebase, a proprietary data warehouse of genomic data matched with antibiotic susceptibility information for bacterial pathogens and its Acuitas Lighthouse informatics, which can be specific to a healthcare facility or collaborator, such as a pharmaceutical company.

The Company's operations are subject to certain risks and uncertainties. The risks include rapid technology changes, the need to manage growth, the need to retain key personnel, the need to protect intellectual property and the need to raise additional capital financing on terms acceptable to the Company. The Company's success depends, in part, on its ability to develop and commercialize its proprietary technology as well as raise additional capital.

OpGen, Inc. ("OpGen" of the "Company") was incorporated in Delaware in 2001. On July 14, 2015, OpGen completed the strategic acquisition (the "Merger") of AdvanDx, Inc. and its wholly owned subsidiary AdvanDx A/S (collectively, "AdvanDx") (see Note 4). Pursuant to the terms of a merger agreement, Velox Acquisition Corp., OpGen's wholly owned subsidiary formed for the express purpose of effecting the Merger, merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as OpGen's wholly owned subsidiary. OpGen, AdvanDx, Inc. and AdvanDx A/S are collectively referred to hereinafter as the "Company." The Company's headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland and Woburn, Massachusetts. The Company also has operations in Copenhagen, Denmark. The Company operates in one business segment.

OpGen is a precision medicine company using molecular diagnostics and bioinformatics to help combat infectious disease. The Company is developing molecular information products and services to combat infectious disease in global healthcare settings, helping to guide clinicians with more rapid information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. Its proprietary DNA tests and bioinformatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize patient care decisions and protect the hospital biome through customized screening and surveillance products and services.

The Company's molecular diagnostics and bioinformatics offerings combine its Acuitas DNA tests, Acuitas Lighthouse bioinformatics services, and CLIA lab services for MDRO surveillance. The Company is working to deliver its products and services, some in development, to a global network of customers and partners. These include:

·	Its Acuitas DNA tests, which provide rapid microbial identification, and antibiotic resistance gene information. These products include the QuickFISH family of FDA- cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures, the Acuitas MDRO Gene Test to detect, type, track, and trend antibiotic resistant organisms in real-time and the Acuitas Rapid Test in development. The Company is working to provide actionable, precise diagnostic information powered by pathogen surveillance data collected through hospital screening programs and a network of hospital and public health laboratories globally.

·	Its Acuitas Lighthouse bioinformatics systems, which are cloud-based HIPAA compliant bioinformatics offerings that combine clinical lab test results with patient and hospital information and provide analytics to help manage MDROs in the hospital and patient care environment. These include its Acuitas Lighthouse informatics, which can be specific to a healthcare facility, public health department or collaborator, such as a pharmaceutical company, and its Acuitas Lighthouse Knowledgebase, a proprietary data warehouse in development to include genomic data matched with antibiotic susceptibility information for microbes and patient information from healthcare providers, in which the Company is beginning to collect and store MDRO information from a variety of sources for use with its Acuitas Rapid Test in development.

Going Concern and Management's Plans

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Liquidation Basis Of Accounting Abstract [Abstract]

Going Concern and Management’s Plans

The accompanying unaudited condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing arrangements and has raised funds in 2017 and 2016, including:

On July 18, 2017 the Company closed a public offering of 18,164,195 units at $0.40 per unit, and 6,835,805 pre-funded units at $0.39 per pre-funded unit, raising gross proceeds of approximately $10 million and net proceeds of approximately $8.8 million (the "July 2017 Public Offering"). jVen Capital, LLC, a Delaware limited liability company ("jVen Capital") was one of the investors participating in the offering. jVen Capital is an affiliate of Evan Jones, the Company's Chairman of the Board and Chief Executive Officer. Each unit included one twenty-fifth of a share of common stock and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share. Each pre-funded unit included one pre-funded warrant to purchase one twenty-fifth of a share of common stock for an exercise price of $0.25 per share, and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share. The common warrants are exercisable immediately and have a five-year term from the date of issuance. Approximately $1 million of the gross proceeds was used to repay the outstanding Bridge Financing Notes (as defined below) in July 2017. Four million pre-funded warrants were exercised in July 2017 (see Note 11 "Subsequent events").

	·	In early June 2017, the Company commenced a restructuring of its operations to improve efficiency and reduce its cost structure. To date, we have achieved a reduction in operating expenses of approximately 25-30 percent. The restructuring plans anticipate that the Company will consolidate operations for FDA-cleared and CE marked products and research and development activities for the Acuitas Rapid Test in Gaithersburg, Maryland, and reduce the size of its commercial organization while the Company works to complete the development of its Acuitas Rapid Test and Acuitas Lighthouse Knowledgebase products and services in development.

	·	On May 31, 2017, the Company entered into a Note Purchase Agreement with jVen Capital, under which jVen Capital agreed to provide bridge financing in an aggregate principal amount of up to $1,500,000 to the Company in up to three separate tranches of $500,000 (each, a "Bridge Financing Note" and collectively, the "Bridge Financing Notes"). The interest rate on each Bridge Financing Note was ten percent (10%) per annum (subject to increase upon an event of default). The Bridge Financing Notes were prepayable by the Company at any time without penalty, and had a maturity date of September 30, 2017, which could be accelerated upon the closing of a qualified financing (any equity or debt financing that raised net proceeds of $5 million or more). The Bridge Financing Notes were contingently convertible at the option of the holder upon an event of default into shares of the Company's convertible Series B preferred stock. In connection with the issuance of Bridge Financing Notes, in June and July 2017, the Company issued jVen Capital stock purchase warrants to acquire 5,633 shares with an exercise price of $19.50 per share, and warrants to acquire 6,349 shares with an exercise price of $17.25 per share. The Company drew down on two of three Bridge Financing Notes during June and July, and repaid such outstanding Bridge Financing Notes in full upon the closing of the July 2017 Public Offering.

As a condition to the receipt of the bridge financing, the Company issued the Second Amended & Restated Senior Secured Promissory Note (the "A&R MGHIF Note") to Merck Global Health Innovation Fund, LLC ("MGHIF"), which extended the maturity date of the promissory note from, July 14, 2017 to July 14, 2018. In return for MGHIF's consent to such extension, the Company increased the interest rate of the A&R MGHIF Note to 10% per annum and issued warrants to purchase shares of common stock to MGHIF equal to 20% of the principal balance of the A&R MGHIF Note, plus interest accrued thereon, as of June 28, 2017.

In September 2016, the Company entered into a Sales Agreement (the "Sales Agreement") with Cowen and Company LLC ("Cowen") pursuant to which the Company may offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. Pursuant to the Sales Agreement, Cowen may sell the shares of the Company's common stock by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act of 1933, as amended (the "Securities Act"), including, without limitation, sales made by means of ordinary brokers' transactions on The Nasdaq Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. The Company pays Cowen compensation equal to 3.0% of the gross proceeds from the sales of common stock pursuant to the terms of the Sales Agreement. As of September 30, 2017, the Company has sold an aggregate of approximately 308 thousand shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $7.8 million, and gross proceeds of $8.4 million. As of September 30, 2017, remaining availability under the at the market offering is $3.1 million. The Company did not sell any shares of its common stock under this at the market offering during the three months ended September 30, 2017. During the nine months ended September 30, 2017, the Company has sold approximately 160 thousand shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $3.4 million, and gross proceeds of $3.6 million.

In May and June 2016, the Company offered and sold units in a private offering to members of management and employees and to accredited investors, including MGHIF and jVen Capital, each unit consisting of either (i) one twenty-fifth of a share of common stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, at a price of $1.14 per unit. The total net proceeds to the Company, after deducting offering commissions and expenses were $9.5 million. The Company used the proceeds for working capital and general corporate purposes. Pursuant to the private placement, the Company issued 269,765 shares of common stock, 2,309,428 shares of non-voting convertible preferred stock and stock purchase warrants to acquire an additional 271,606 shares of common stock. Holders of the non-voting convertible preferred stock subsequently converted all 2,309,428 shares of preferred stock into 92,377 shares of common stock. The stock purchase warrants issued as part of the units are exercisable at a price of $32.8125 per share beginning 90 days after closing for five years, expiring on May 18, 2021.

To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, strategic financings or other transactions, additional equity financings, debt financings and other funding transactions, licensing and/or partnering arrangements and business combination transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The Company believes that current cash on hand will be sufficient to fund operations into the first quarter of 2018. This has led management to conclude that substantial doubt about the Company's ability to continue as a going concern exists. In the event the Company is unable to successfully raise additional capital during or before the first quarter of 2018, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing. If such sufficient financing is not received on a timely basis, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection.

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing arrangements and has raised significant funds in 2016 and 2015, including:

On September 13, 2016, the Company entered into the Sales Agreement with Cowen pursuant to which the Company may offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. Pursuant to the Sales Agreement, Cowen may sell the shares of common stock by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act, including, without limitation, sales made by means of ordinary brokers' transactions on The Nasdaq Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. The Company pays Cowen compensation equal to 3.0% of the gross proceeds from the sales of common stock pursuant to the terms of the Sales Agreement. As of December 31, 2016, the Company has sold an aggregate of approximately 144 thousand shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $4.4 million, and gross proceeds of $4.7 million. As of December 31, 2016, under the initial sales agreement, remaining availability under the at the market offering is $6.8 million. Subsequent to December 31, 2016, the Company has sold an aggregate of approximately 84 thousand shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $2.1 million, and gross proceeds of $2.2 million. Under the initial sales agreement, remaining availability under the at the market offering is $4.6 million.

In May and June 2016, the Company offered and sold units in a private offering to members of management and employees and to accredited investors, including Merck GHI and jVen Capital, each unit consisting of either (i) one twenty-fifth of a share of common stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, at a price of $1.14 per unit. The total net proceeds to the Company, after deducting offering commissions and expenses was $9.5 million. Pursuant to the private placement, the Company issued 269,765 shares of common stock, 2,309,428 of non-voting convertible preferred stock and stock purchase warrants to acquire an additional 271,606 shares of common stock.

In July 2015, the Company raised $6.0 million by issuing 45,454 shares of common stock at $110.0 per share and a $1.0 million senior secured promissory note to Merck GHI. Under the Purchase Agreement, Merck GHI has the right to participate in future securities offerings made by the Company (see Note 5).

In May 2015, OpGen completed its IPO for total gross proceeds of $17.1 million (see Note 8).

To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, additional equity financings, debt financings and other funding transactions, licensing and/or partnering arrangements and business combination transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The Company believes that current cash on hand will be sufficient to fund operations into the second quarter of 2017. This has led management to conclude that substantial doubt about the Company's ability to continue as a going concern exists. In the event the Company is unable to successfully raise additional capital during or before the second quarter of 2017, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing. If such sufficient financing is not received timely, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. Furthermore, the $1.0 million senior secured promissory note matures in July 2017. If the Company is unable to repay the note, negotiate its conversion or extend its term, the assets of the Company may be seized, as the note is secured by a lien on all the Company's assets.

Liquidity and management's plans

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Liquidation Basis Of Accounting Abstract [Abstract]

Liquidity and management's plans

	·	In early June 2017, the Company commenced a restructuring of its operations to improve efficiency and reduce its cost structure. To date, we have achieved a reduction in operating expenses of approximately 25-30 percent. The restructuring plans anticipate that the Company will consolidate operations for FDA-cleared and CE marked products and research and development activities for the Acuitas Rapid Test in Gaithersburg, Maryland, and reduce the size of its commercial organization while the Company works to complete the development of its Acuitas Rapid Test and Acuitas Lighthouse Knowledgebase products and services in development.

	·	On May 31, 2017, the Company entered into a Note Purchase Agreement with jVen Capital, under which jVen Capital agreed to provide bridge financing in an aggregate principal amount of up to $1,500,000 to the Company in up to three separate tranches of $500,000 (each, a "Bridge Financing Note" and collectively, the "Bridge Financing Notes"). The interest rate on each Bridge Financing Note was ten percent (10%) per annum (subject to increase upon an event of default). The Bridge Financing Notes were prepayable by the Company at any time without penalty, and had a maturity date of September 30, 2017, which could be accelerated upon the closing of a qualified financing (any equity or debt financing that raised net proceeds of $5 million or more). The Bridge Financing Notes were contingently convertible at the option of the holder upon an event of default into shares of the Company's convertible Series B preferred stock. In connection with the issuance of Bridge Financing Notes, in June and July 2017, the Company issued jVen Capital stock purchase warrants to acquire 5,633 shares with an exercise price of $19.50 per share, and warrants to acquire 6,349 shares with an exercise price of $17.25 per share. The Company drew down on two of three Bridge Financing Notes during June and July, and repaid such outstanding Bridge Financing Notes in full upon the closing of the July 2017 Public Offering.

In May 2015, OpGen completed its IPO for total gross proceeds of $17.1 million (see Note 8).

Summary of Significant Accounting Policies Basis of Presentation

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of presentation and consolidation

The Company has prepared the accompanying unaudited condensed, consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") and the standards of accounting measurement set forth in the Interim Reporting Topic of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"). Certain information and note disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP") have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. The Company recommends that the following unaudited condensed, consolidated financial statements be read in conjunction with the audited condensed, consolidated financial statements and the notes thereto included in the Company's latest Annual Report on Form 10-K. In the opinion of management, all adjustments that are necessary for a fair presentation of the Company's financial position for the periods presented have been reflected. All adjustments are of a normal, recurring nature, unless otherwise stated. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2016 consolidated balance sheet included herein was derived from the audited consolidated financial statements, but do not include all disclosures including notes required by GAAP for complete financial statements.

The accompanying unaudited condensed consolidated financial statements include the accounts of OpGen and its wholly-owned subsidiaries; all intercompany transactions and balances have been eliminated. The Company operates in one business segment.

Foreign currency

One of the Company's subsidiaries is located in Copenhagen, Denmark and uses the Danish Krone as its functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in accumulated other comprehensive (loss)/income, a component of stockholders' equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive (loss)/income at September 30, 2017 and December 31, 2016.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss. Unless otherwise noted, all references to "$" or "dollar" refer to the U.S. dollar.

Use of estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventory obsolescence, valuation of derivative financial instruments and other liabilities measured at fair value on a recurring basis, deferred tax assets and liabilities and related valuation allowance, depreciation and amortization and estimated useful lives of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

Financial instruments classified as current assets and liabilities (including cash and cash equivalent, receivables, accounts payable, deferred revenue and short-term notes) are carried at cost, which approximates fair value, because of the short-term maturities of those instruments.

Cash and cash equivalents

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency ("FDIC") insured limits of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

At September 30, 2017 and December 31, 2016, the Company has funds totaling $243,380, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. These funds are reflected in other noncurrent assets on the accompanying unaudited condensed consolidated balance sheets.

Accounts receivable

The Company's accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer's financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 60 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company's previous loss history and the customer's current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $24,783 and $26,716 as of September 30, 2017 and December 31, 2016, respectively.

No individual customer represented in excess of 10% of revenues for the three months ended September 30, 2017. Revenue earned from one customer represented 11% of total revenues for the three months ended September 30, 2016. No individual customer represented in excess of 10% of revenues for the nine months ended September 30, 2017 and 2016. At September 30, 2017, no individual customer represented in excess of 10% of total accounts receivable. At September 30, 2016, accounts receivable from one customer represented 11% of the total accounts receivable.

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	September 30, 2017		December 31, 2016
Raw materials and supplies	$	279,562	$	479,479
Work-in process		40,814		27,422
Finished goods		140,753		185,467
Total	$	461,129	$	692,368

Inventory includes reagents and components for QuickFISH and PNA FISH kit products, and reagents and supplies used for the Company's laboratory services. Inventory reserves for obsolescence and expirations were $157,529 and $704,516 at September 30, 2017 and December 31, 2016, respectively. The primary driver of the decrease in the inventory reserves for obsolescence and expirations is the disposal of legacy Argus Whole Genome Mapping Systems and the portion of the reagents and supplies used for Argus consumable kits. All items disposed in the nine months ended September 30, 2017 related to Argus were fully reserved for as of December 31, 2016.

Long-lived assets

Property and equipment

Property and equipment is reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three and nine months ended September 30, 2017 and 2016, the Company determined that its property and equipment was not impaired.

Intangible assets and goodwill

Intangible assets and goodwill as of September 30, 2017 consist of finite-lived intangible assets and goodwill.

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships and consisted of the following as of September 30, 2017 and December 31, 2016:

			September 30, 2017					December 31, 2016
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(102,153	)	$	358,847	$	(67,575	)	$	393,425
Developed technology		458,000		(144,966	)		313,034		(95,898	)		362,102
Customer relationships		1,094,000		(345,745	)		748,255		(228,529	)		865,471
	$	2,013,000	$	(592,864	)	$	1,420,136	$	(392,002	)	$	1,620,998

Finite-lived intangible assets are amortized over their estimated useful lives. The estimated useful life of trademarks was 10 years, developed technology was 7 years, and customer relationships was 7 years. The Company reviews the useful lives of intangible assets when events or changes in circumstances occur which may potentially impact the estimated useful life of the intangible assets.

Total amortization expense of intangible assets was $66,954 for each of the three months ended September 30, 2017 and 2016. Total amortization expense of intangible assets was $200,862 for each of the nine months ended September 30, 2017 and 2016, respectively. The Company estimates amortization expense related to intangible assets will be $268,000 per year for each of the next five years.

Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the three and nine months ended September 30, 2017 and 2016, the Company determined that its finite-lived intangible assets were not impaired.

In accordance with ASC 360-10, Property, Plant and Equipment, the Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. During the fourth quarter of 2016, events and circumstances indicated the Company's intangible assets might be impaired. However, management's estimate of undiscounted cash flows indicated that such carrying amounts were expected to be recovered. Nonetheless, it is reasonably possible that the estimate of undiscounted cash flows may change in the near term resulting in the need to write down those assets to fair value. Management's estimate of cash flows might change if the Company's commercial operations are negatively impacted by the consolidation of operations for the FDA-cleared and CE marked products to Gaithersburg, Maryland or if there is an unfavorable development of sales trends.

Goodwill

Goodwill represents the excess of the purchase price paid in a July 2015 merger transaction in which the Company acquired AdvanDx, Inc. and its subsidiary (the "Merger") over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is not tax deductible in any relevant jurisdictions. The Company's goodwill balance as of September 30, 2017 and December 31, 2016 was $600,814.

The Company conducts an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company's fair value below its net equity value.

Revenue recognition

The Company recognizes revenue primarily from sales of its products and services when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics.

Amounts billed to customers for shipping and handling are included in revenue when the related product or service revenue is recognized. Shipping and handling costs are included in cost of products sold.

Revenue from sales of QuickFISH, PNA FISH and XpressFISH diagnostic test products

Revenue is recognized upon shipment to the customer.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

The Company's funded software development arrangements generally consist of multiple elements. Total arrangement consideration is allocated to the identified units of accounting based on their relative selling prices and revenue is then recognized for each unit based on its specific characteristics. When funded software development arrangements include substantive research and development milestones, revenue is recognized for each such milestone when the milestone is achieved and is due and collectible. Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement and the related risk associated with achievement of the milestone.

Revenue from license arrangements

The Company recognizes revenue from licenses of its technologies over the applicable license term.

Revenue from sales of the reagents and supplies used for Argus consumable kits

Revenue is recognized for sales of the reagents and supplies used for Argus consumable kits upon shipment to the customer.

Share-based compensation

Share-based compensation expense is recognized at fair value. The fair value of share-based compensation to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. The Company accounts for forfeitures as they occur.

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized.

Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.

The Company had federal net operating loss ("NOL") carryforwards of $151.0 million at December 31, 2016. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the "Code"). To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Code. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

Recent accounting pronouncements

In May 2014, the FASB issued an Accounting Standards Update ("ASU") for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenue arising from contracts with customers. In August 2015, the FASB issued guidance approving a one-year deferral, making the standard effective for reporting periods beginning after December 15, 2017, with early adoption permitted only for reporting periods beginning after December 15, 2016. In March 2016, the FASB issued guidance to clarify the implementation guidance on principal versus agent considerations for reporting revenue gross rather than net, with the same deferred effective date. In April 2016, the FASB issued guidance to clarify the identification of performance obligations and licensing arrangements. In May 2016, the FASB issued guidance addressing the presentation of sales and other similar taxes collected from customers, providing clarification of the collectability criterion assessment, as well as clarifying certain transition requirements. The Company has identified its major revenue streams and it plans on completing formal contract reviews in the fourth quarter of 2017. While the Company continues to assess all of the potential impacts of these ASUs, the Company does not expect the implementation of these ASUs to have a significant impact on the Company's results of operations, financial position or cash flows.

In July 2015, the FASB issued accounting guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The standard is effective for reporting periods beginning after December 15, 2016. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company adopted this guidance effective January 1, 2017 on a prospective basis. The adoption of this new guidance did not have a material impact on the Company's consolidated financial statements.

In February 2016, the FASB issued guidance for the accounting for leases. The guidance requires lessees to recognize assets and liabilities related to long-term leases on the consolidated balance sheets and expands disclosure requirements regarding leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018 and early adoption is permitted. The guidance must be adopted on a modified retrospective basis and provides for certain practical expedients. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.

The Company has evaluated all other issued and unadopted ASUs and believes the adoption of these standards will not have a material impact on its results of operations, financial position or cash flows.

The accompanying consolidated financial statements are prepared in accordance with generally accepted accounting standards in the United States ("U.S. GAAP"). The consolidated financial statements consolidate the operations of all controlled subsidiaries; all intercompany activity is eliminated. Certain prior period information has been reclassified to conform to the current period presentation.

Foreign Currency

AdvanDx A/S is located in Copenhagen, Denmark and uses the Danish Kroner as its functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in accumulated other comprehensive income/(loss), a component of stockholders' equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at December 31, 2016 and 2015.

Use of Estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventory obsolescence, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

All financial instruments classified as current assets and liabilities are carried at cost, which approximates fair value, because of the short-term maturities of those instruments. For additional fair value disclosures, see Note 13.

Cash and cash equivalents and restricted cash

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

As of December 31, 2016 and 2015, the Company has funds totaling $243,380, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. These funds are reflected in other noncurrent assets on the accompanying consolidated balance sheets.

Accounts Receivable

The Company's accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer's financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 60 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company's previous loss history and the customer's current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $26,716 and $15,596 as of December 31, 2016 and 2015, respectively.

At December 31, 2016, the Company had accounts receivable from one customer, a related party, which individually represented 25% of total accounts receivable. At December 31, 2015, the Company had accounts receivable from one customer which individually represent 25% of total accounts receivable. No individual customer represented in excess of 10% of revenues for year ended December 31, 2016. For the year ended December 31, 2015, revenue earned from Hitachi High-Technologies Corporation ("Hitachi") represented 11% of total revenues.

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	December 31, 2016		December 31, 2015
Raw materials and supplies	$	479,479	$	362,526
Work-in process		27,422		150,369
Finished goods		185,467		313,117
Total	$	692,368	$	826,012

Inventory includes reagents and components for QuickFISH and PNA FISH kit products, Argus Whole Genome Mapping Systems, reagents and supplies used for Argus consumable kits, and reagents and supplies used for the Company's laboratory services. Inventory reserves for obsolescence and expirations were $704,516 and $591,051 at December 31, 2016 and 2015, respectively.

Long-lived assets

Property and equipment

Property and equipment is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets. The estimated service lives approximate three to five years. Depreciation expense was $388,231 and $500,467 for the years ended December 31, 2016 and 2015, respectively. Property and equipment consisted of the following at December 31, 2016 and 2015:

	December 31,
	2016			2015
Laboratory and manufacturing equipment	$	3,785,133		$	3,734,044
Office furniture and equipment		688,952			701,557
Computers and network equipment		1,472,144			1,563,177
Leasehold improvements		662,506			659,949
		6,608,735			6,658,727
Less accumulated depreciation		(5,808,012	)		(5,584,017	)
Property and equipment, net	$	800,723		$	1,074,710

In 2012, the Company began to provide Argus™ Whole Genome Systems under its Argus Reagent Rental Program to customers, in which the Company retains title without requiring customers to purchase the equipment or enter into an equipment lease or rental contract. The costs associated with these instruments are capitalized and charged to sales and marketing on a straight-line basis over the estimated useful life of the instrument, which is approximately four years. During the years ended December 31, 2016 and 2015, sales and marketing expenses related to these costs were $0 and approximately $175,000, respectively. The costs to maintain these systems are charged to operations as incurred.

Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the years ended December 31, 2016 and 2015, the Company determined that its property and equipment was not impaired.

Intangible assets and goodwill

Intangible assets and goodwill as of December 31, 2016 were acquired as part of the Merger, and consist of finite-lived intangible assets and goodwill.

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships, and consisted of the following as of December 31, 2016 and 2015:

			December 31, 2016					December 31, 2015
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(67,575	)	$	393,425	$	(21,471	)	$	439,529
Developed technology		458,000		(95,898	)		362,102		(30,474	)		427,526
Customer relationships		1,094,000		(228,529	)		865,471		(72,241	)		1,021,759
	$	2,013,000	$	(392,002	)	$	1,620,998	$	(124,186	)	$	1,888,814

Total amortization expense of intangible assets was $267,816 and $124,186 for the years ended December 31, 2016 and 2015, respectively. Amortization of intangible assets is expected to be approximately $268,000 per year for the next five years.

Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During years ended December 31, 2016 and 2015, the Company determined that its finite-lived intangible assets were not impaired.

In accordance with ASC 360-10, the Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. During the fourth quarter of 2016, events and circumstances indicated the Company's intangible assets might be impaired. However, management's estimate of undiscounted cash flows indicated that such carrying amounts were expected to be recovered. Nonetheless, it is reasonably possible that the estimate of undiscounted cash flows may change in the near term resulting in the need to write down those assets to fair value. Management's estimate of cash flows might change if the development of the Company's automated rapid pathogen identification product technological advances does not progress as planned, the timeline of development is delayed, there are changes to the estimates of the future marketability of this product or if the Company cannot obtain sufficient funding to pay for its development.

Goodwill

Goodwill represents the excess of the purchase price for AdvanDx over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is not tax deductible in any relevant jurisdictions.

Deferred rent

Deferred rent is recorded and amortized to the extent the total minimum rental payments allocated to the current period on a straight-line basis exceed or are less than the cash payments required.

Revenue recognition

The Company recognizes revenue primarily from sales of its products and services when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative fair value and revenue is then recognized for each unit based on its specific characteristics.

Revenue from sales of QuickFISH, PNA FISH and XpressFISH diagnostic test products

Revenue is recognized upon shipment to the customer.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

Revenue from license arrangements

The Company recognizes revenue from licenses of its technologies over the applicable license term.

Revenue from sales of the Argus System

When an Argus System is sold without the Genome Builder software, total arrangement consideration is recognized as revenue when the system is delivered to the customer. Ancillary performance obligations, including installation, limited customer training and limited consumables, are considered inconsequential and are combined with the Argus System as one unit of accounting.

When an Argus System is sold with the Genome Builder software in a multiple-element arrangement, total arrangement consideration is allocated to the Argus System and to the Genome Builder software based on their relative selling prices. Selling prices are determined based on sales of similar systems to similar customers and, where no sales have occurred, on management's best estimate of the expected selling price relative to similar products. Revenue related to the Argus System is recognized when it is delivered to the customer; revenue for the Genome Builder software is recognized when it is delivered to the customer.

Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)

Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.

Revenue from extended warranty service contracts

The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.

Research and development costs

Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and related expenses for personnel, other resources, laboratory supplies, fees paid to consultants and outside service partners.

Share-based compensation

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant- date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. A discussion of management's methodology for developing each of the assumptions used in the Black-Scholes model is as follows:

Fair value of common stock

For periods prior to the Company's IPO, given the lack of an active public market for the common stock, the Company's board of directors determined the fair value of the common stock. In the absence of a public market, and as an emerging company with no significant revenues, the Company believed that it was appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. The factors included: (1) the achievement of clinical and operational milestones by the Company; (2) the status of strategic relationships with collaborators; (3) the significant risks associated with the Company's stage of development; (4) capital market conditions for life science and medical diagnostic companies, particularly similarly situated, privately held, early stage companies; (5) the Company's available cash, financial condition and results of operations; (6) the most recent sales of the Company's preferred stock; and (7) the preferential rights of the outstanding preferred stock. Since the IPO, the Company uses the quoted market price of its common stock as its fair value.

Expected volatility

Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. Until a significant trading history for its common stock develops, the Company has identified several public entities of similar size, complexity and stage of development; accordingly, historical volatility has been calculated using the volatility of this peer group.

Expected dividend yield

The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.

Risk-free interest rate

This is the U.S. Treasury rate for the day of each option grant during the year, having a term that most closely resembles the expected term of the option.

Expected term

This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of 10 years. The Company estimates the expected term of the option to be 6.25 years for options with a standard four-year vesting period, using the simplified method. Over time, management will track actual terms of the options and adjust their estimate accordingly so that estimates will approximate actual behavior for similar options.

Income taxes

The Company had federal net operating loss ("NOL") carryforwards of $150,950,436 and $132,359,334 at December 31, 2016 and 2015, respectively. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the "Code"). To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Code. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted- average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) stock purchase warrants, and (iii) restricted stock units representing the right to acquire shares of common stock which have been excluded from the computation of diluted loss per share, was 540 thousand shares and 240 thousand shares as of December 31, 2016 and 2015, respectively. The Company's convertible preferred stock, prior to its conversion, contained non-forfeitable rights to dividends, and therefore was considered to be a participating security; the calculation of basic and diluted income (loss) per share excludes net income (but not net loss) attributable to the convertible preferred stock from the numerator and excludes the impact of those shares from the denominator in periods prior to the IPO.

Recent accounting pronouncements

In May 2014, the Financial Accounting Standards Board ("FASB") issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: 1) identify the contract, 2) identify performance obligations, 3) determine the transaction price, 4) allocate the transaction price, and 5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing, and uncertainty of revenue arising from contracts with customers. In August 2015, the FASB issued guidance approving a one-year deferral, making the standard effective for reporting periods beginning after December 15, 2017, with early adoption permitted only for reporting periods beginning after December 15, 2016. In March 2016, the FASB issued guidance to clarify the implementation guidance on principal versus agent considerations for reporting revenue gross rather than net, with the same deferred effective date. In April 2016, the FASB issued guidance to clarify the identification of performance obligations and licensing arrangements. In May 2016, the FASB issued guidance addressing the presentation of sales and other similar taxes collected from customers, providing clarification of the collectability criterion assessment, as well as clarifying certain transition requirements. The Company is currently evaluating the impact, if any, that this guidance will have on its consolidated financial statements.

In August 2014, the FASB issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity's ability to continue as a going concern. The guidance 1) provides a definition for the term "substantial doubt," 2) requires an evaluation every reporting period, interim periods included, 3) provides principles for considering the mitigating effect of management's plans to alleviate the substantial doubt, 4) requires certain disclosures if the substantial doubt is alleviated as a result of management's plans, 5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and 6) requires an assessment period of one year from the date the financial statements are issued. This guidance is effective for the annual periods ending after December 15, 2016 and for annual and interim reporting periods thereafter. The Company has made the appropriate disclosures required by this guidance. The adoption of this guidance has had no financial statement impact.

In April 2015, the FASB issued accounting guidance requiring that debt issuance costs related to a recognized liability be presented on the balance sheet as a direct reduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected. The standard is effective for reporting periods beginning after December 15, 2015. The Company adopted this guidance effective January 1, 2016 on a retrospective basis, and all periods are presented under this guidance.

In April 2015, the FASB issued guidance as to whether a cloud computing arrangement (e.g., software as a service, platform as a service, infrastructure as a service, and other similar hosting arrangements) includes a software license and, based on that determination, how to account for such arrangements. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. The guidance is effective for reporting periods beginning after December 15, 2015, and can be adopted on either a prospective or retrospective basis. The Company adopted this guidance for the year ended December 31, 2016, on a prospective basis. The adoption of this new guidance did not have a material impact on the Company's consolidated financial statements.

In July 2015, the FASB issued accounting guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The standard is effective for reporting periods beginning after December 15, 2016. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.

In March 2016, the FASB issued guidance simplifying the accounting for and financial statement disclosure of stock-based compensation awards. Under the guidance, all excess tax benefits and tax deficiencies related to stock-based compensation awards are to be recognized as income tax expenses or benefits in the income statement and excess tax benefits should be classified along with other income tax cash flows in the operating activities section of the statement of cash flows. Under the guidance, companies can also elect to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. In addition, the guidance amends some of the other stock-based compensation awards guidance to more clearly articulate the requirements and cash flow presentation for withholding shares for tax-withholding purposes. The guidance is effective for reporting periods beginning after December 15, 2016 and early adoption is permitted, though all amendments of the guidance must be adopted in the same period. The Company elected to adopt the guidance effective for the fiscal year ended December 31, 2016 and apply it retrospectively for all periods presented. This has not materially impacted the Company's consolidated results of operations, financial position or cash flows.

The Company has evaluated all other issued and unadopted Accounting Standards Updates and believes the adoption of these standards will not have a material impact on its results of operations, financial position, or cash flows.

Business Combination

12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Business Combination

On July 14, 2015, the Company acquired 100% of the capital stock of AdvanDx in the Merger in a taxable transaction. AdvanDx researches, develops and markets advanced IVD kits for the diagnosis and prevention of infectious diseases, and sells its products principally to hospitals and clinical laboratories in the United States and Europe. The Company acquired AdvanDx principally to use AdvanDx's diagnostic capabilities with respect to MDROs and leverage AdvanDx's relationships with hospitals and clinical laboratories to accelerate the sales of OpGen's products and services.

Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), Velox Acquisition Corp. merged with and into AdvanDx, Inc. with AdvanDx, Inc. surviving as a wholly owned subsidiary of the Company in accordance with the General Corporation Law of the State of Delaware. Under the terms of the Merger Agreement, the merger consideration consisted of an aggregate 681,818 shares of the Company's common stock with a value of $2.6 million (the "Merger Consideration"), which Merger Consideration was distributed in accordance with the liquidation preferences set forth in the AdvanDx, Inc. Restated Certificate of Incorporation, as amended.

The Company accounted for its acquisition of AdvanDx by recording all tangible and intangible assets acquired and liabilities assumed at their estimated fair values on the acquisition date, with the remaining unallocated purchase price recorded as goodwill. The fair value assigned to identifiable intangible assets acquired was determined using an income approach for trade names and customer relationships, and a cost approach for technology. The Company received carryover tax basis in the acquired assets and liabilities and no tax basis in the intangible assets (including goodwill) established on the acquisition date. As a result, the Company recognized deferred tax assets related to foreign taxing jurisdictions of $4.3 million (fully offset by a corresponding valuation allowance) and net deferred tax liabilities of $0.1 million in the U.S. taxing jurisdiction. The net deferred tax liability in the U.S. taxing jurisdiction resulted in an income tax benefit related to a reduction in the Company's previously established valuation allowance (which reduction is accounted for outside of purchase accounting). The following represents the allocation of the purchase price (as adjusted for measurement period adjustments):

Total purchase price – fair value of common stock issued	$	2,584,090
Fair value of tangible assets acquired:
Cash	$	1,367,211
Receivables		536,406
Inventory		881,273
Property and equipment		245,479
Other assets		359,587
Fair value of identifiable intangible assets acquired:
Customer relationships		1,094,000
Developed technology		458,000
Trademarks and tradenames		461,000
Fair value of goodwill		600,814
Deferred tax liabilities, net		129,095
Fair value of liabilities assumed		3,290,585
	$	2,584,090

The total consideration paid in the acquisition exceeded the estimated fair value of the tangible and identifiable intangible assets acquired and liabilities assumed, resulting in approximately $0.6 million of goodwill. Goodwill, primarily related to expected synergies gained from combining operations, sales growth from future product offerings and customers, together with certain intangible assets that do not qualify for separate recognition, including assembled workforce, is not tax deductible.

Adjustments to goodwill

In the fourth quarter of 2015, the Company adopted new accounting guidance with respect to the accounting for measurement period adjustments resulting from business combinations. Under the new guidance, the Company is required to recognize adjustments to provisional amounts identified during the measurement period in the reporting period in which the adjustments are determined and disclose the portion of the amount recorded in current-period losses by line item that would have been recorded in previous reporting periods if the adjustment had been recognized as of the acquisition date.

During the fourth quarter of 2015, as a result of obtaining new information about facts and circumstances that existed as of the acquisition date, the Company adjusted the provisional estimated fair values of certain acquired assets and liabilities acquired in the Merger, resulting in an increase in goodwill recognized of $345,781. During the first quarter of 2016, the Company identified an additional adjustment to the provisional estimated fair values, resulting in a decrease in goodwill recognized of $36,714.

Pro Forma Disclosures (unaudited)

The following unaudited pro forma financial information summarizes the results of operations for the year ended December 31, 2015 as if the Merger had been completed as of January 1, 2015. Pro forma information primarily reflects adjustments relating to (i) elimination of the interest on AdvanDx's outstanding debt, and (ii) the amortization of intangibles acquired. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition occurred as of January 1, 2014 or that may be obtained in the future:

	December 31,
Unaudited pro forma results	2015
Revenues	$	5,231,844
Net loss	$	(20,751,552	)
Net loss per share	$	(63.00	)

Merck GHI Financing

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Common Stock And Note Purchase Agreement [Abstract]

Merck GHI Financing

In July 2015, in connection with the Merger, the Company entered into a Purchase Agreement with MGHIF, pursuant to which MGHIF purchased 45,454 shares of common stock of the Company at $110.00 per share for gross proceeds of $5.0 million. Pursuant to the Purchase Agreement, the Company also issued to MGHIF an 8% Senior Secured Promissory Note (the "MGHIF Note") in the principal amount of $1.0 million with a two-year maturity date from the date of issuance. The Company's obligations under the MGHIF Note are secured by a lien on all of the Company's assets. Under the Purchase Agreement, MGHIF has the right to participate in future securities offerings made by the Company. Also in July 2015, the Company entered into a Registration Rights Agreement with MGHIF and certain stockholders, which will require the Company to register for resale by such holders in the future, such shares of Company common stock that cannot be sold under an exemption from such registration.

The Company incurred issuance costs of approximately $50,000 related to the financing. Approximately $8,000 of the issuance costs were deferred as debt issuance costs and netted against notes payable in the accompanying condensed consolidated balance sheets is a result of the Company's adoption of the new accounting guidance in 2016, and are being amortized as interest expense over the life of the MGHIF Note. The remaining $42,000 of issuance costs were charged to additional paid-in capital.

On June 6, 2017, the promissory note was amended and restated, and the maturity date of the A&R MGHIF Note was extended by one year to July 14, 2018. As consideration for the agreement to extend the maturity date, the Company issued an amended and restated secured promissory note to MGHIF that (1) increased the interest rate to ten percent (10%) per annum and (2) provided for the issuance of common stock warrants to purchase 13,119 shares of its common stock to MGHIF . The warrants issued to MGHIF each have a five year term from issuance, are first exercisable on the date that is six months after the date of issuance and have an exercise price equal $19.50 which represents 110% of the closing price of the Company's common stock on the date of issuance.

The A&R MGHIF Note was treated as a debt modification and as such the issuance date fair value of the warrants is deferred and amortized as incremental interest expense over the term of A&R MGHIF Note. The warrants are classified as mark to market liabilities under ASC 480, Distinguishing Liabilities from Equity, due to certain put features that allow the holder to put the warrant back to the Company for cash equal to the Black-Scholes value of the warrant upon a change of control or fundamental transaction, as defined in the agreement. The warrants had an issuance date fair value of approximately $0.1 million which was calculated using the Black-Scholes model.

The estimated fair value of the A&R MGHIF Note was $1.0 million as of September 30, 2017 and December 31, 2016 which approximates the carry value given the short time lapse since modification, prevailing interest rates and maturity date

On July 14, 2015, as a condition of the Merger, the Company entered into the Purchase Agreement with Merck GHI, pursuant to which Merck GHI purchased 45,454 shares of common stock of the Company at $110.00 per share for gross proceeds of $5.0 million. Pursuant to the Purchase Agreement, the Company also issued to Merck GHI a 8% Senior Secured Promissory Note (the "Merck Note") in the principal amount of $1.0 million with a two-year maturity date from the date of issuance. The Company's obligations under the Merck Note are secured by a lien on all of the Company's assets. Under the Purchase Agreement, Merck GHI has the right to participate in future securities offerings made by the Company. Also in July 2015, the Company entered into a Registration Rights Agreement with Merck GHI and the AdvanDx stockholders who received shares of the Company's common stock in the Merger, which will require the Company to register for resale by such holders in the future, such shares of Company common stock that cannot be sold under an exemption from such registration.

The Company incurred issuance costs of approximately $50,000 related to the financing. Approximately $8,000 of the issuance costs were deferred as debt issuance costs and netted against notes payable in the accompanying consolidated balance sheets as a result of the Company's adoption of the new accounting guidance in 2016 (see Note 3), and are being amortized as interest expense over the life of the Merck Note. The remaining $42,000 of issuance costs were charged to additional paid-in capital.

Redeemable Convertible Preferred Stock

12 Months Ended

Dec. 31, 2016

Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]

Redeemable Convertible Preferred Stock

All shares of Series A Preferred Stock (including those shares issued in connection with the conversion of the 2014 and 2015 convertible debt) were converted into 294,994 shares of common stock in connection with the Company's IPO (see Notes 7 and 8). Before such conversion, the Series A Preferred Stock was redeemable at the option of the holders of 70% of the outstanding shares of Series A Preferred Stock, subject to certain additional requirements. The Company's redeemable convertible preferred stock was classified as temporary equity due to redemption provisions outside of the Company's control.

The Company issued 1,999,864 shares of Series A Preferred Stock in December 2013 at $1.00 per share in exchange for $1,999,864 in convertible promissory notes. In February 2014, the Company sold 1,405,096 shares of Series A redeemable convertible preferred stock for gross proceeds of $1,405,096. In April 2014, the Company sold an additional 594,904 shares of Series A Preferred Stock for gross proceeds of $594,904. The Company incurred issuance costs of $62,098 related to the 2014 Series A Preferred Stock sales.

The following table presents the changes in the Series A Preferred Stock during 2015:

	Shares			Amount
Balance at December 31, 2014		3,999,864		$	4,564,899
2015 Accretion		—			243,762
2015 Conversions		(3,999,864	)		(4,808,661	)
Balance at December 31, 2015		—		$	—

The Series A Preferred Stock had the right to receive non-cumulative dividends, at a rate of 8% per annum, when and if declared by the board of directors. The Series A Preferred Stock had preference of payment over all other classes and series of capital stock of the Company with respect to dividends, payment on liquidation and payment on redemption. The liquidation and redemption preferences were at two times the Series A Preferred Stock purchase price. The Series A preferred stockholders were entitled to vote on all matters that come to stockholders on an as-converted basis with holders of the common stock. In addition, the Series A Preferred Stock had broad based anti-dilution rights.

The holders of Series A Preferred Stock had the right to convert such shares, at their option and at any time, into shares of common stock at the then-applicable conversion rate, as defined. The initial conversion rate was one common share for each preferred share, which may be adjusted for specified dilutive transactions. Beginning in December 2019, the Company may have been obligated to redeem shares of Series A Preferred Stock, if requested, by holders of at least 70% of the then-outstanding shares of preferred stock. The redemption, if requested, would have taken place in three equal annual installments. Series A Preferred Stock would have been redeemed at two times the original issue price per share plus all accrued and unpaid dividends. The redemptions were subject to certain equity adjustments for specified anti-dilution transactions, as defined.

Debt

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Debt Disclosure [Abstract]

Debt

As of September 30, 2017, the Company's outstanding short-term debt consisted of the $1.0 million MGHIF Note, net of discounts and financing costs (see Note 4 "2015 MGHIF financing") as well as, the financing arrangements for the Company's insurance with note balances of approximately $0.2 million with a final payment scheduled for May 2018. Total principal payments of $0.2 million are due in 2017 and $1.0 million are due in 2018. As of December 31, 2016, the Company's outstanding long-term debt consisted of the $1.0 million MGHIF Note, net of discounts and financing costs.

The Company drew down on two of three Bridge Financing Notes (see discussion in Note 2 "Liquidity and management's plans) during June and July of 2017. The outstanding Bridge Financing Notes were repaid in full subsequent to the closing of the July 2017 Public Offering.

The Company accounted for the embedded conversion option granted to jVen Capital in the Bridge Financing Notes as a mark-to-market derivative financial instrument carried at fair value. Changes in fair value of the embedded conversion option are reflected in earnings during the period of change. The embedded conversion option was expensed along with the remaining unamortized discount at the date of the Bridge Financing Notes repayment. The warrants issued to jVen Capital and MGHIF are classified as mark-to-market liabilities under ASC 480 due to certain put features that allow the holder to put the warrant back to the Company for cash equal to the Black-Scholes value of the warrant upon a change of control or fundamental transaction.

Total interest expense (including amortization of debt discounts and financing fees) on all debt instruments was $90,317 and $41,423 for the three months ended September 30, 2017 and 2016, respectively. Total interest expense (including amortization of debt discounts and financing fees) on all debt instruments was $173,974 and $109,806 for the nine months ended September 30, 2017 and 2016, respectively.

As of December 31, 2016, the Company's outstanding debt consisted of the $1.0 million Merck Note that is due in July 2017 (see Note 5). As of December 31, 2015, debt outstanding consisted of the $1.0 million Merck Note.

Demand notes

In the fourth quarter of 2014 and first quarter of 2015, the Company raised a total of $2.3 million through the issuance of short-term demand notes. In the first quarter of 2015, $0.3 million of demand notes, held by an entity controlled by our chief executive officer, were settled as partial payment for a 2015 convertible note. All then-outstanding demand notes were tendered as payment for 350,000 units in the Company's IPO (see Note 8). Prior to settlement, the demand notes bore interest at 8% per annum, had a first priority security interest in the assets of the Company, and a term of approximately four months.

2014 convertible debt

In July, August and September 2014, the Company raised $1.5 million through the issuance of convertible debt. All outstanding 2014 convertible debt was converted into Series A redeemable convertible preferred stock and then into 60,000 shares of common stock in connection with the Company's IPO (see Note 8). Prior to its conversion, the debt was convertible, at the option of the holders or in certain cases at the Company's option, into shares of Series A redeemable convertible preferred stock or other potential equity securities, bore interest at 8% and was due in full on July 11, 2015.

2015 convertible debt

In February and March 2015, the Company raised $1.5 million in capital through the issuance of 8% secured convertible notes with detachable stock purchase warrants. All outstanding 2015 convertible debt was converted into Series A redeemable convertible preferred stock and then into 75,000 shares of common stock in connection with the Company's IPO (see Note 8). Prior to its conversion, the 2015 convertible notes were prepayable by the Company without penalty at any time following the three-month anniversary of the closing of the IPO (provided that before the six-month anniversary of the closing of an IPO, the 2015 convertible notes could only be prepaid out of newly issued capital subsequent to the IPO), and were puttable by the holder to the Company in the event of a defined default. The 2015 convertible notes were each convertible, at the election of the holder, into (i) shares of Series A redeemable convertible preferred stock, at a conversion rate of 1.25 shares of Series A redeemable convertible preferred stock for each $1.00 converted if the conversion occurs prior to closing of an IPO, or (ii) shares of common stock at a conversion rate of one twenty-fifth of a share of common stock for each $1.00 converted if the conversion occurs after the closing of an IPO.

The conversion option embedded in the convertible notes was determined to contain beneficial conversion features, resulting in the bifurcation of those features as an equity instrument (resulting in an additional debt discount) at issuance. After allocation of the gross proceeds to the detachable stock purchase warrants (discussed below) and beneficial conversion feature, the total debt discount recognized was equal to the face value of the 2015 convertible notes. Upon conversion in May 2015, the remaining unamortized beneficial conversion feature of approximately $1.5 million was charged to interest expense in the accompanying condensed consolidated statements of operations and comprehensive loss.

Remaining unamortized deferred financing costs of $71,421 were also charged to interest expense upon conversion.

The 2015 convertible note holders also received detachable stock purchase warrants exercisable for 9,000 shares of common stock at 110% of the IPO price and exercisable only if the IPO occurred, and then exercisable beginning on the six-month anniversary of the closing of the IPO. Prior to the IPO, as a result of net settlement features, the stock purchase warrants were considered derivative liabilities, were initially recorded at fair value (resulting in a debt discount) and were marked-to-market at each balance sheet date through earnings. As a result of the elimination of the net settlement features in the IPO, the stock purchase warrants were marked to fair value of $0.7 million on May 8, 2015 and then reclassified to equity.

Total interest expense on all debt instruments was $143,347 for the year ended December 31, 2016. Total interest expense on all debt instruments was $1,801,320 for year ended December 31, 2015.

Stockholders' Equity

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Stockholders' Equity Note [Abstract]

Stockholders' Equity

As of September 30, 2017, the Company has 200,000,000 shares of authorized common stock and 2,078,595 shares issued and outstanding, and 10,000,000 authorized preferred shares, of which none were issued or outstanding.

In the July 2017 Public Offering, the Company issued 18,164,195 units at $0.40 per unit, and 6,835,805 pre-funded units at $0.39 per pre-funded unit, raising gross proceeds of approximately $10 million and net proceeds of approximately $8.8 million. jVen Capital was one of the investors participating in the offering. Each unit included one twenty-fifth of a share of common stock and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share. Each pre-funded unit included one pre-funded warrant to purchase one twenty-fifth of a share of common stock for an exercise price of $0.25 per share, and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share. The common warrants are exercisable immediately and have a five-year term from the date of issuance. At closing, the outstanding Bridge Financing Notes issued to jVen Capital, were repaid in the principal amount of $1 million plus accrued interest of $6,438. Four million pre-funded warrants were exercised during the three months ended September 30, 2017 (see Note 11 "Subsequent events").

In connection with the July 2017 Public Offering, the Company issued to its placement agent 50,000 shares of common stock. The warrants issued to the Placement Agent have an exercise price of $12.50 per share and are exercisable for five years.

In September 2016, the Company entered into the Sales Agreement with Cowen pursuant to which the Company may offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. Pursuant to the Sales Agreement, Cowen may sell the shares of common stock by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act, including, without limitation, sales made by means of ordinary brokers' transactions on the Nasdaq Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. The Company pays Cowen compensation equal to 3.0% of the gross proceeds from the sales of common stock pursuant to the terms of the Sales Agreement. As of September 30, 2017, the Company has sold an aggregate of approximately 308 thousand shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $7.8 million, and gross proceeds of $8.4 million. As of September 30, 2017, remaining availability under the at the market offering is $3.1 million. The Company did not sell any shares of its common stock under this at the market offering during the three months ended September 30, 2017. During the nine months ended September 30, 2017, the Company has sold approximately 160 thousand shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $3.4 million, and gross proceeds of $3.6 million.

In May and June 2016, the Company offered and sold units in a private offering to members of management and employees and to accredited investors, including MGHIF and jVen Capital, each unit consisting of either (i) one twenty-fifth of a share of common stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, at a price of $1.14 per unit. The total net proceeds to the Company, after deducting offering commissions and expenses was $9.5 million. Pursuant to the private placement the Company issued 269,765 shares of common stock, 2,309,428 of Series A non-voting convertible preferred stock and stock purchase warrants to acquire an additional 271,606 shares of common stock. Under the purchase agreement, the Company granted registration rights to the investors in the private financing.

Each share of Series A non-voting convertible preferred stock was convertible at the option of the holder in whole or in part and from time to time into one twenty-fifth of a share of common stock, was entitled to dividends on an "as converted basis" when and if dividends are issued to common stockholders, and would have participated in liquidation on a pari passu basis with common stockholders. The preferred stock was classified as permanent equity. The stock purchase warrants issued as part of the units are exercisable at $32.8125 per share beginning 90 days after closing for five years, expiring on May 18, 2021. The warrants are classified as permanent equity at September 30, 2017. In connection with the issuance of Series A non-voting convertible preferred stock, the Company recognized a beneficial conversion feature of $332,550 as a deemed dividend to the preferred shareholders. Holders of the Series A non-voting convertible preferred stock subsequently converted all 2,309,428 shares of preferred stock into 92,377 shares of common stock.

The Company filed a registration statement on Form S-3 on June 13, 2016 to register for resale by the investors, from time to time, of the shares of common stock acquired, or underlying the warrants issued, in the private offering. On July 20, 2016, the registration statement was declared effective by the SEC.

Stock options

In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan (the "2008 Plan"), pursuant to which the Company's Board of Directors could grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Company adopted, and the Company's stockholders approved, the 2015 Equity Incentive Plan (the "2015 Plan"); the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company's initial public offering in May 2015. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 54,200 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan's effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan's effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company's Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of September 30, 2017, 34,767 shares remain available for issuance under the 2015 Plan, which includes 40,486 shares automatically added to the 2015 Plan on January 1, 2017.

On April 28, 2016, the Board of Directors of the Company made a stock option award to Evan Jones, the Company's Chief Executive Officer ("CEO") and Chairman of the Board. The non-qualified stock option award to acquire 30,660 shares of common stock represented approximately 6% of outstanding shares of common stock as of the date of the award. The stock option grant has an exercise price of $33.75 per share, a ten-year term and a vesting schedule of 25% vesting of the award on the first annual anniversary of the date of grant and then 6.25% vesting each quarter thereafter over three additional years. The plan under which the award was made incorporates by reference the provisions of the Company's 2015 Plan applicable to stock option awards. The stock option award was contingent on receipt of stockholder approval, as the award was made outside of the Company's stockholder-approved incentive plans. The stockholders approved the stock option award at the Company's Annual Meeting of Stockholders held on June 22, 2016.

For the three and nine months ended September 30, 2017 and 2016, the Company recognized stock compensation expense as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Cost of services	$	2,306	$	—	$	6,274	$	5,008
Research and development		61,097		45,945		171,652		181,367
General and administrative		187,357		98,683		500,252		447,811
Sales and marketing		16,832		34,124		44,126		72,462
	$	267,592	$	178,752	$	722,304	$	706,648

No income tax benefit for stock-based compensation arrangements was recognized in the condensed consolidated statements of operations and comprehensive loss due to the Company's net loss position.

During the three months ended September 30, 2017, the Company granted stock options to acquire 16,380 shares of common stock at a weighted average exercise price of $7.50 per share and a weighted average grant date fair value of $3.00 per share. 7,851 options were forfeited during the three months ended September 30, 2017 at a weighted average exercise price of $27.75 per share.

During the nine months ended September 30, 2017, the Company granted stock options to acquire 51,164 shares of common stock at a weighted average exercise price of $19.00 per share and a weighted average grant date fair value of $9.50 per share. 20,167 options were forfeited during the nine months ended September 30, 2017 at a weighted average exercise price of $33.25 per share. The Company had total stock options to acquire 138,869 shares of common stock outstanding at September 30, 2017.

Restricted stock units

During the three and nine months ended September 30, 2017, the Company granted restricted stock units to acquire 11,575 shares of common stock, with a weighted average grant date fair value of $7.00. 1,060 restricted stock units vested and no restricted stock units were forfeited during the three and nine months ended September 30, 2017. The Company had 11,265 total restricted stock units outstanding at September 30, 2017.

Stock purchase warrants

At September 30, 2017 and December 31, 2016, the following warrants to purchase shares of common stock were outstanding:

				Underlying Warrant Shares at
Issuance	Exercise Price		Expiration	September 30, 2017		December 31, 2016
August 2007	$	197.75	August 2017		—		356
March 2008	$	19,763.50	March 2018		1		1
November 2009	$	197.75	November 2019		266		266
January 2010	$	197.75	January 2020		266		266
March 2010	$	197.75	March 2020		51		51
November 2011	$	197.75	November 2021		208		208
December 2011	$	197.75	December 2021		26		26
March 2012	$	109.90	March 2019		165		165
February 2015	$	165.00	February 2025		9,000		9,000
May 2015	$	165.00	May 2020		138,310		138,310
May 2016	$	32.75	May 2021		189,573		189,573
June 2016	$	32.75	May 2021		82,032		82,032
June 2017	$	19,50	June 2022		18,753		—
July 2017	$	17.25	July 2022		6,349		—
July 2017	$	12.50	July 2022		50,000		—
July 2017 (1)	$	0.25	July 2022		113,432		—
July 2017	$	10.75	July 2022		1,000,000		—
					1,608,439		420,260

The warrants listed above were issued in connection with various debt, equity or development contract agreements.

(1) These July 2017 warrants represent the outstanding pre-funded warrants issued under the July 2017 Public Offering. See Note 7 "Stockholders' equity" and Note 11 "Subsequent events."

As of December 31, 2016, the Company has 200,000,000 shares of authorized common shares and 1,012,170 issued and outstanding, and 10,000,000 of authorized preferred shares, none of which were issued or outstanding.

On September 13, 2016, the Company entered into the Sales Agreement with Cowen pursuant to which the Company may offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. Pursuant to the Sales Agreement, Cowen may sell the shares of common stock by any method permitted by law deemed to be an "at the market" offering as defined in Rule 415 of the Securities Act, including, without limitation, sales made by means of ordinary brokers' transactions on The Nasdaq Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. The Company pays Cowen compensation equal to 3.0% of the gross proceeds from the sales of common stock pursuant to the terms of the Sales Agreement. As of December 31, 2016, the Company has sold an aggregate of approximately 144 thousand shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $4.4 million, and gross proceeds of $4.7 million. As of December 31, 2016, remaining availability under the at the market offering is $6.8 million.

Subsequent to December 31, 2016, the Company has sold an aggregate of approximately 84 thousand shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $2.1 million, and gross proceeds of $2.2 million. Under the initial sales agreement, remaining availability under the at the market offering is $4.6 million.

On May 19, 2016 and June 27, 2016, the Company offered and sold units in a private offering to members of management and employees and to accredited investors, including Merck GHI and jVen Capital, each unit consisting of either (i) one twenty-fifth of a share of common stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, at a price of $1.14 per unit. The total net proceeds to the Company, after deducting offering commissions and expenses was $9.5 million. Pursuant to the private placement the Company issued 269,765 shares of common stock, 2,309,428 of Series A non-voting convertible preferred stock and stock purchase warrants to acquire an additional 271,606 shares of common stock. Under the purchase agreement, the Company granted registration rights to the investors in the private financing.

Each share of Series A non-voting convertible preferred stock was convertible at the option of the holder in whole or in part and from time to time into one twenty-fifth of a share of common stock, was entitled to dividends on as "as converted basis" when and if dividends are issued to common stockholders, and participates in liquidation on a pari passu basis with common stockholders. The preferred stock was classified as permanent equity. The stock purchase warrants issued as part of the units are exercisable $32.8125 per share beginning 90 days after closing for five years, expiring on May 18, 2021. The warrants are classified as permanent equity at December 31, 2016. In connection with the issuance of Series A non-voting convertible preferred stock, the Company recognized a beneficial conversion feature of $332,550 as a deemed dividend to the preferred stockholders. Holders of the Series A non-voting convertible preferred stock subsequently converted all 2,309,428 shares of preferred stock into 92,377 shares of common stock in July 2016. The shares of preferred stock were retired and are no longer available for future issuance.

In July 2015, the Company issued 45,454 shares of common stock to Merck GHI for cash consideration of $5.0 million (see Note 5).

On May 8, 2015, the Company completed its IPO pursuant to which the Company offered and sold 2,850,000 units, each unit consisting of one twenty-fifth of a share of common stock and a detachable stock purchase warrant to purchase an additional one twenty-fifth of a share of common stock, at an initial offering price of $6.00 per unit. Of the total gross proceeds of $17.1 million, approximately $2.1 million was used to satisfy outstanding demand notes by exchanging such notes for 350,000 units in the IPO. After considering the demand notes, and underwriting discounts, commissions and offering expenses of $2.9 million (which were charged to additional paid-in capital), the total net cash proceeds to the Company was $12.1 million. On the IPO closing date, the underwriters exercised a portion of their over-allotment option to acquire additional stock purchase warrants to purchase an additional 16,900 shares of common stock for cash of $4,225.

In connection with the IPO, all of the Company's outstanding Series A redeemable convertible preferred stock, 2014 convertible notes and 2015 convertible notes were converted into 294,994 shares of common stock. Prior to the IPO, the carrying value of the Series A redeemable convertible preferred stock was increased by the accretion of related discounts, issuance costs and accrued but unpaid dividends so that the carrying amount would equal the redemption amount at the dates the stock becomes redeemable.

The stock purchase warrants issued as part of the units (including over-allotment option) are exercisable for 130,900 shares of common stock at $165.00 per share beginning six months after the closing of the IPO for five years, expiring on May 8, 2020. Additionally, the Company issued additional warrants to its investment bankers to purchase 7,410 shares of common stock, on the same terms as the warrants issued with the units. The warrants were valued using the Black-Scholes option pricing model and are classified as equity.

Stock options

In 2008, the Board adopted, and the stockholders approved, the 2008 Stock Option and Restricted Stock Plan (the "2008 Plan"), pursuant to which the Company's Board of Directors may grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Board adopted, and the Company's stockholders approved, the 2015 Equity Incentive Plan (the "2015 Plan"); the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company's IPO. Following the effectiveness of the 2015 Plan, no further grants have been made under the 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Code to employees and the granting of non-qualified stock options to employees, non- employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 54,200 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan's effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan's effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company's Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of December 31, 2016, 26,786 shares remain available for issuance under the 2015 Plan.

For the years ended December 31, 2016 and 2015, the Company recognized stock compensation expense as follows:

	Year Ended December 31,
	2016		2015
Cost of services	$	6,003	$	—
Research and development		236,341		240,739
General and administrative		599,550		619,899
Sales and marketing		103,567		584,450
	$	945,461	$	1,445,088

No income tax benefit for stock-based compensation arrangements was recognized in the consolidated statements of operations due to the Company's net loss position.

As of December 31, 2016, the Company had unrecognized expense related to its stock options of $2.2 million, which will be recognized over a weighted average period of 1.17 years.

A summary of the status of options granted is presented below as of and for the years ended December 31, 2016 and 2015:

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2015		16,170					9.3	$	—
Granted		78,465			$67.00
Exercised		(458	)		$5.00			$	19,519
Forfeited		(7,746	)		$13.75
Outstanding at December 31, 2015		86,431			$65.00		9.1	$	1,575,646
Granted		58,546			$35.25
Exercised		(2,660	)		$9.00			$	79,406
Forfeited		(22,867	)		$99.75
Expired		(343	)		$212.25
Outstanding at December 31, 2016		119,106			$44.00		8.6	$	663,298
Vested and expected to vest		119,106			$44.00		8.6	$	663,298
Exercisable at December 31, 2016		43,940			$5.50		8.0	$	421,621

The total fair value of options vested in the years ended December 31, 2016 and 2015, was $1,088,978 and $1,140,079, respectively. The fair value of each option grant was estimated at the date of grant using the Black-Scholes option pricing model based on the assumptions below:

	Year Ended December 31,
	2016	2015
Annual dividend	—	—
Expected life (in years)	5.25 – 6.25	5.5 – 6.25
Risk free interest rate	1.2 – 2.2%	1.5 – 1.9%
Expected volatility	42.0 – 49.8%	47.7 – 65.0%

The Company issued an annual grant on February 22, 2017 of 28,932 options to employees at an exercise price of $25.75 per share.

Restricted stock units

In the fourth quarter of 2015, the Company granted restricted stock units to acquire 3,000 shares of common stock, with a weighted average grant date fair value of $42.50 per share, 750 shares of which remain outstanding as of December 31, 2016. 266 restricted stock units vested and 1,583 restricted stock units were forfeited during the year ended December 31, 2016 at a weighted average grant date fair value of $42.50 per share.

Stock purchase warrants

At December 31, 2016 and 2015, the following warrants to purchase shares of common stock were outstanding:

				Underlying Warrant Shares at December 31,
Issuance	Exercise Price		Expiration	2016		2015
August 2007	$	197.75	August 2017		356		356
March 2008	$	19,763.50	March 2018		1		1
November 2009	$	197.75	November 2019		266		266
January 2010	$	197.75	January 2020		266		266
March 2010	$	197.75	March 2020		51		51
November 2011	$	197.75	November 2021		208		208
December 2011	$	197.75	December 2021		26		26
March 2012	$	2,747.50	March 2019		165		165
February 2015	$	165.00	February 2025		9,000		9,000
May 2015	$	165.00	May 2020		138,310		138,310
May 2016	$	32.75	May 2021		189,573		—
June 2016	$	32.75	May 2021		82,032		—
					420,260		148,654

The warrants listed above were issued in connection with various equity, debt, preferred stock or development contract agreements. The warrants issued in February 2015 were initially classified as a liability since the exercise price was variable. The exercise price became fixed as a result of the Company's IPO and, as such, the warrant liability was marked to fair value at that time and reclassified to equity (see Note 13).

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

At December 31, 2016 and 2015, the Company had net deferred tax assets of $63,520,548 and $41,554,045, respectively, primarily consisting of NOL carry forwards, research and experimental ("R&E") credits, and differences between depreciation and amortization recorded for financial statement and tax purposes. The Company's net deferred tax assets at December 31, 2016 and 2015 have been offset by a valuation allowance of $63,520,548 and $41,554,045, respectively. The valuation allowance has been recorded due to the uncertainty of realization of the deferred tax assets. The Company's deferred tax assets and liabilities as of December 31, 2016 and 2015 are as follows:

	December 31,
	2016			2015
Deferred tax assets:
NOL carryforward	$	60,357,220		$	38,797,762
R&E credit carryforward		2,559,479			1,994,478
Share-based compensation		448,534			383,153
Inventory reserve		269,708			226,299
Depreciation		117,629			313,714
Accruals and other		333,126			495,640
Total deferred tax assets		64,085,696			42,211,046
Valuation allowance		(63,520,548	)		(41,554,045	)
Deferred tax liabilities:
Intangible assets		(565,148	)		(657,001	)
Fixed assets		—			—
Net deferred tax liability	$	—		$	—

The difference between the Company's expected income tax provision (benefit) from applying federal statutory tax rates to the pre-tax loss and actual income tax provision (benefit) relates to the effect of the following:

	2016			2015
Federal income tax benefit at statutory rates		34.0	%		34.0	%
State income tax benefit, net of Federal benefit		6.5	%		3.3	%
Change in valuation allowance		(37.3	)%		(32.1	)%
Change in state tax rates and other		(3.2	)%		(4.5	)%
		0.0	%		0.7	%

Additionally, despite the NOL carryforwards, the Company may have future tax liability due to alternative minimum tax or state tax requirements. The Company has federal NOL carryforwards of $150,950,436 and $132,359,334 at December 31, 2016 and 2015, respectively. The NOL carry forwards begin to expire in 2022. Utilization of the NOL carryforward may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code. There can be no assurance that the NOL carryforward will ever be fully utilized. To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Internal Revenue Code of 1986, as amended. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Commitments

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments

Operating leases

The Company leases a facility in Woburn, Massachusetts under an operating lease that expires January 30, 2022. The Company also leases a facility in Gaithersburg, Maryland under an operating lease that expires January 31, 2021, with one additional five-year renewal at the Company's election. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis.

Rent expense under the Company's facility operating leases for the three months ended September 30, 2017 and 2016 was $238,791 and $254,219, respectively. Rent expense under the Company's facility operating leases for the nine months ended September 30, 2017 and 2016 was $710,330 and $756,608, respectively.

Capital leases

Registration and other stockholder rights

In connection with the various investment transactions, the Company entered into registration rights agreements with stockholders, pursuant to which the investors were granted certain demand registration rights and/or piggyback and/or resale registration rights in connection with subsequent registered offerings of the Company's common stock.

Restructuring

In early June 2017, the Company commenced a restructuring of its operations to improve efficiency and reduce its cost structure. To date, we have achieved a reduction in operating expenses of approximately 25-30 percent. The restructuring plans anticipate that the Company will consolidate operations for FDA-cleared and CE marked products and research and development activities for the Acuitas Rapid Test in Gaithersburg, Maryland, and reduce the size of its commercial organization while the Company works to complete the development of its Acuitas Rapid Test and Acuitas Lighthouse Knowledgebase products and services in development.

There were approximately $0 and $121,000 of one-time termination benefits that were recognized during the three and nine months ended September 30, 2017 related to the restructuring. The Company does not anticipate any further one-time termination benefits related to the restructuring plan. Retention agreements were issued to certain employees in which retention bonuses are earned and paid upon the completion of a designated service period. The service periods ends in December 2017. The Company expects to incur total retention expense of approximately $68,000 of which approximately $34,000 and $47,000 was incurred during the three and nine months ended September 30, 2017. The future minimum lease payments for the Woburn facility were approximately $1.8 million as of September 30, 2017. A liability for costs that will continue to be incurred under a contract for its remaining term without economic benefit to the entity shall be recognized at the cease-use date. If the contract is an operating lease the fair value of the liability at the cease-use date shall be determined based on the remaining lease rentals, adjusted for the effects of any prepaid or deferred items recognized under the lease, and reduced by estimated sublease rentals that could be reasonably obtained for the property. The Company expects the cease-use date for the Woburn facility to be in the first quarter of 2018. We have not estimated the contract termination costs associated with this lease given that we have not yet reached the cease use date and given that we have only begun preliminary sublease pursuit activities. We do not believe there will be significant additional costs related to restructuring outside of what is described herein.

Operating leases

The Company leases a facility in Woburn, Massachusetts under an operating lease that expires January 30, 2022.

During the second quarter of 2015, the Company extended the term of its Gaithersburg, Maryland office lease, effective May 7, 2015, through January 31, 2021, with one additional five- year renewal at the Company's election. The Company is responsible for all utilities, repairs, insurance, and taxes under this operating lease. Effective July 1, 2015, the Company further modified its lease agreement to add additional leased space to its headquarters. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis.

Rent expense under the Company's facility operating leases for the year ended December 31, 2016 and 2015 was $1,000,726 and $683,519, respectively.

Capital leases

The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2021. The leases require monthly principal and interest payments. Following is a schedule by year of the estimated future minimum payments under all operating and capital leases as of December 31, 2016:

Year ending December 31,	Capital Leases			Operating Leases		Total
2017	$	204,354		$	1,072,448	$	1,276,802
2018		113,337			1,205,263		1,318,600
2019		21,266			427,769		449,035
2020		21,266			427,769		449,035
2021 and thereafter		1,773			463,416		465,189
Total	$	361,996		$	3,596,665	$	3,958,661
Less: amount representing interest		(31,054	)
Net present value of future minimum lease payments	$	330,942
Current maturities		(184,399	)
Long-term maturities	$	146,543

Assets under capital leases were included in the following balance sheet categories as of December 31:

	2016			2015
Laboratory and manufacturing equipment	$	560,829		$	803,500
Office furniture and equipment		64,790			89,140
Computers and network equipment		24,350			153,693
Less accumulated amortization		(270,808	)		(402,066	)
Capital lease assets, net	$	379,161		$	644,267

Amortization expense associated with equipment under capital leases for the years ended December 31, 2016 and 2015 was $161,606 and $157,036, respectively, and is included within depreciation and amortization expense in the consolidated statements of operations.

Registration and other stockholder rights

License Agreements, Research Collaborations and Development Agreements

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

License Agreements Research Collaborations And Development Agreements [Abstract]

License Agreements, Research Collaborations and Development Agreements

The Company is a party to one license agreement to acquire certain patent rights and technologies related to its FISH product line. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. The Company recognized net royalty expense of $62,500 and $71,135 for the three months ended September 30, 2017 and 2016, respectively. Under all license agreements, the Company recognized a net royalty expense of $194,686 and $216,937 for the nine months ended September 30, 2017 and 2016, respectively. Annual future minimum royalty fees are $250,000 under these agreements.

In June 2016, the Company entered into a license agreement with Hitachi High-Technologies Corporation ("Hitachi"), pursuant to which it resolved various matters with respect to previously delivered milestones under the technology development agreement and provided a development license and commercial products license to certain technology. The license agreement contains non-contingent multiple elements (the licenses) that the Company determined did not have stand alone value, and a contingent substantive milestone. The licenses are treated as a single unit of accounting and the Company will recognize the revenue associated with that unit of accounting over the applicable license period. During the three and nine months ended September 30, 2017, the Company recognized $6,301 and $18,698, respectively, of revenue related to the license agreement.

The Company is a party to five license agreements to acquire certain patent rights and technologies; two related to the FISH product line and three related to the Argus and MapIt product lines. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. Certain of the agreements require the Company to pay minimum royalties or license maintenance fees. The Company recognized net royalty expense of $290,491 and $205,147 for the years ended December 31, 2016 and 2015, respectively. Annual future minimum royalty fees are $250,000 under these agreements.

In September 2013, the Company entered into a technology development agreement with Hitachi High-Technologies Corporation ("Hitachi") that included fixed milestone payments for meeting development milestones under the agreement. Since the milestones were substantive, the Company recognized revenue in the periods in which the substantive milestones were achieved. In addition, the Company received an upfront payment which was recognized on a straight-line basis over the term of the technology development agreement, which ended on December 31, 2015. The Company recognized total revenue of $336,102 for the year ended December 31, 2015 (none in 2016), relating to this arrangement.

In June 2016, the Company entered into a license agreement with Hitachi, pursuant to which it resolved various matters with respect to previously delivered milestones under the technology development agreement and provided a development license and commercial products license to certain technology. The license agreement contains non-contingent multiple elements (the licenses) that the Company determined did not have stand alone value, and a contingent substantive milestone. The licenses are treated as a single unit of accounting and the Company will recognize the revenue associated with that unit of accounting over the applicable license period. During the year ended December 31, 2016, the Company recognized $137,603 of revenue related to the license agreement.

Related Party Transactions

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Related Party Transactions

In March 2014, the Company entered into a supply agreement (the "Supply Agreement") with Fluidigm Corporation ("Fluidigm") under which Fluidigm supplies the Company with its microfluidic test platform for use in manufacturing the Acuitas MDRO Gene Test. The Company's CEO and Chairman of the Board of Directors is a director of Fluidigm. On July 12, 2015, the Company entered into a letter agreement (the "Fluidigm Agreement") with Fluidigm to expand the companies' existing relationship to include collaborating on the development of test kits and custom analytic instruments for identification, screening and surveillance testing of MDROs. The Fluidigm Agreement also expanded the Supply Agreement, and provides for expansion of the gene targets and organisms to be tested on the Company's existing CLIA lab-based tests, the Acuitas MDRO Gene Test and the Acuitas Resistome Test, using Fluidigm technologies and products. Additionally, Fluidigm has agreed not to develop or directly collaborate with any third party to develop an FDA approved or CE-marked diagnostic test for the purpose of detecting resistance genes for identified MDROs if the Company meets certain minimum purchase commitments and other requirements. The initial term of the Fluidigm Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term was extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms. The Company paid $30,200 and $0 related to these agreements in the three months ended September 30, 2017 and 2016, respectively. The Company paid $74,921 and $160,089 related to these agreements in the nine months ended September 30, 2017 and 2016, respectively.

Under the Supply Agreement, the Company had inventory purchases of $19,760 and $23,624 in the three months ended September 30, 2017 and 2016, respectively. Under the Supply Agreement, the Company had inventory purchases of $110,239 and $91,399 in the nine months ended September 30, 2017 and 2016, respectively.

In addition, the Company has several capital lease arrangements for laboratory equipment manufactured by Fluidigm. The Company paid $15,683 and $45,106 related to the leased equipment in the three months ended September 30, 2017 and 2016, respectively. The Company paid $76,199 and $135,319 related to the leased equipment in the nine months ended September 30, 2017 and 2016, respectively.

In October 2016, the Company entered into an agreement with Merck Sharp & Dohme Corp., a wholly-owned subsidiary of Merck Co. & Inc. ("Merck"), an affiliate of MGHIF, a principal stockholder of the Company and a related party to the Company. Under the agreement, Merck provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. Merck gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs. The Company is required to expend up to $175,000 for the procurement of materials related to the activities contemplated by the agreement. Contract life-to-date, the Company has incurred $146,177 of procurement costs which have been recognized as research and development expense, including $0 and $113,907 in the three and nine months ended September 30, 2017, respectively.

In March 2014, the Company entered into a supply agreement with Fluidigm Corporation ("Fluidigm") under which Fluidigm supplies the Company with its microfluidic test platform for use in manufacturing the Acuitas MDRO Gene Test. The Company's CEO and Chairman of the Board of Directors is a director of Fluidigm. On July 12, 2015, the Company entered into a letter agreement (the "Fluidigm Agreement") with Fluidigm to expand the companies' existing relationship to include collaborating on the development of test kits and custom analytic instruments for identification, screening and surveillance testing of MDROs. The Fluidigm Agreement also expands the existing Supply Agreement between the Company and Fluidigm, and provides for expansion of the gene targets and organisms to be tested on the Company's existing CLIA lab-based tests, the Acuitas MDRO Gene Test and the Acuitas Resistome Test, using Fluidigm technologies and products. Additionally, Fluidigm has agreed not to develop or directly collaborate with any third party to develop an FDA approved or CE marked diagnostic test for the purpose of detecting resistance genes for identified MDROs if the Company meets certain minimum purchase commitments and other requirements. The initial term of the Fluidigm Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term was extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms. The Company paid $183,713 related to these agreements in the year ended December 31, 2016. The Company paid $295,442 related to these agreements in the year ended December 31, 2015.

Under the agreements with Fluidigm, the Company had purchases of $91,399 in the year ended December 31, 2016. The Company had purchases of $370,539 related to these agreements in the year ended December 31, 2015.

In addition, the Company has several capital lease arrangements for laboratory equipment manufactured by Fluidigm. The Company paid $175,475 related to the leased equipment in the year ended December 31, 2016. The Company paid $119,919 related to the leased equipment in the year ended December 31, 2015.

In October 2016, the Company entered into an agreement with Merck Sharp & Dohme Corp., a wholly owned subsidiary of Merck Co. & Inc. ("Merck"), an affiliate of Merck Global Health Innovation Fund ("Merck GHI"), a principal stockholder of the Company and a related party to the Company. Under the agreement, Merck will provide access to its archive of over 200,000 bacterial pathogens. OpGen will initially perform molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of OpGen's rapid diagnostic products. Merck will gain access to the high-resolution genotype data for the isolates as well as access to OpGen's Acuitas Lighthouse informatics to support internal research and development programs. OpGen is required to expend up to $175,000 for the procurement of materials related to the activities contemplated by the agreement. As of December 31, 2016, the Company has incurred $32,270 of procurement costs which have been recognized as research and development expense.

In December 2016, the Company entered into an agreement with Healthcare Services & Solutions LLC, an affiliate of Merck GHI, in which the Company will provide research analysis and reports to the third party. The agreement is worth up to $150,000, of which $135,000 has been recognized as of December 31, 2016. At December 31, 2016, the Company had accounts receivable from this customer of $135,000, which individually represented 25% of total accounts receivable.

Fair Value Measurements

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

	·	Level 1 - defined as observable inputs such as quoted prices in active markets;
	·	Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.

For the nine months ended September 30, 2017, the Company has not transferred any assets between fair value measurement levels.

Financial assets and liabilities measured at fair value on a recurring basis

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy.

As part of the Company's bridge financing and amendment to the A&R MGHIF Note, the Company issued stock purchase warrants that the Company considers to be mark-to-market liabilities due to certain put features that allow the holder to put the warrant back to the Company for cash equal to the Black-Scholes value of the warrant upon a change of control or fundamental transaction. The Company determines the fair value of the warrant liabilities using the Black-Scholes option pricing model. Using this model, level 3 unobservable inputs include the estimated volatility of the Company's common stock, estimated terms of the instruments, and estimated risk-free interest rates.

The Company originally accounted for the conversion option embedded in the Bridge Financing Notes as a mark-to-market derivative financial instrument. The Company determined the fair value of the embedded conversion option liability using a probability-weighted expected return method. Using this method, level 3 unobservable inputs include the probability of default, the probability of a qualified financing, the probability of conversion, the estimated volatility of the Company's common stock, estimated terms of the instruments, and estimated risk-free interest rates, among other inputs. The fair value of the conversion option was expensed at the time of repayment of the Bridge Financing Notes.

The following table sets forth a summary of changes in the fair value of level 3 liabilities measured at fair value on a recurring basis for the three and nine months ended September 30, 2017:

Description

Balance at

December 31,

2016

Established

in 2017

Changes

in Fair

Value

Expensed

Balance at

September 30,

2017

Embedded conversion option liability

—

4,500

—

(4,500

)

—

Warrant liability

—

152,517

(124,139

)

—

28,378

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when they are deemed to be impaired. No such fair value impairment was recognized in the three and nine months ended September 30, 2017 and 2016.

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

·	Level 1 – defined as observable inputs such as quoted prices in active markets;
·	Level 2 – defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

·	Level 3 – defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.

Financial assets and liabilities measured at fair value on a recurring basis

Prior to its IPO, certain stock purchase warrants contained cash settlement features and, accordingly, the Company considered them to be derivative financial instruments and accounted for them at fair value using level 3 inputs. As a result of the Company's IPO and elimination of the cash settlement features pursuant to their terms, those stock purchase warrants were reclassified to equity. For periods prior to the IPO, the Company determined the fair value of these derivative liabilities using a hybrid valuation method that consisted of a probability weighted expected return method that values the Company's equity securities assuming various possible future economic outcomes while using an option pricing method (that treated all equity linked instruments as call options on the Company's equity value with exercise prices based on the liquidation preference of the Series A Preferred Stock) to estimate the allocation of value within one or more of the scenarios. Using this hybrid method, unobservable inputs included the Company's equity value, the exercise price for each option value, expected timing of possible economic outcomes such as initial public offering, risk free interest rates and stock price volatility. The following tables set forth a summary of changes in the fair value of Level 3 liabilities measured at fair value on a recurring basis for the year ended December 31, 2015 (there has been no activity for the year ended December 31, 2016):

Description

Balance at

December 31,

2014

Established in 2015

Change in Fair Value

Reclassified to Equity

Balance at

December 31,

2015

Derivative warrant liability

—

72,333

647,342

(719,675

)

—

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

See Note 4 for a discussion of the fair value of assets acquired and liabilities assumed in the Merger.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Subsequent Events

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Subsequent Events [Abstract]

Subsequent events

As of October 16, 2017, all of the 6,835,805 pre-funded warrants issued in the July 2017 Public Offering have been exercised.

On January 17, 2018, the Board of Directors of the Company approved a one-for-twenty-five reverse stock split. All share and per share information in these consolidated financial statements, except for par value and authorized shares, have been amended to reflect the reverse stock split.

In addition, on January 17, 2018, the stockholders of the Company approved an Amendment to the Amended and Restated Certificate of Incorporation to reduce the number of authorized shares of common stock from 200,000,000 to 50,000,000.

Summary of Significant Accounting Policies Basis of Presentation (Policies)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Accounting Policies [Abstract]

Basis of Presentation And Consolidation

Foreign Currency

Use of Estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, share-based compensation, allowances for doubtful accounts and inventory obsolescence, valuation of derivative financial instruments, beneficial conversion features of convertible debt, deferred tax assets and liabilities and related valuation allowance, and depreciation and amortization and estimated useful lives of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

Cash and cash equivalents and restricted cash

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (FDIC) insured limits of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

Accounts Receivable

The Company's accounts receivable result from revenues earned but not collected from customers. Credit is extended based on an evaluation of a customer's financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 60 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company's previous loss history and the customer's current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $26,716 and $15,596 as of December 31, 2016 and 2015, respectively.

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	September 30, 2017		December 31, 2016
Raw materials and supplies	$	279,562	$	479,479
Work-in process		40,814		27,422
Finished goods		140,753		185,467
Total	$	461,129	$	692,368

Inventories are valued using the first-in, first-out method and stated at the lower of cost or market and consist of the following:

	December 31, 2016		December 31, 2015
Raw materials and supplies	$	479,479	$	362,526
Work-in process		27,422		150,369
Finished goods		185,467		313,117
Total	$	692,368	$	826,012

Long-lived assets

Property and equipment

Intangible assets and goodwill

Intangible assets and goodwill as of September 30, 2017 consist of finite-lived intangible assets and goodwill.

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships and consisted of the following as of September 30, 2017 and December 31, 2016:

			September 30, 2017					December 31, 2016
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(102,153	)	$	358,847	$	(67,575	)	$	393,425
Developed technology		458,000		(144,966	)		313,034		(95,898	)		362,102
Customer relationships		1,094,000		(345,745	)		748,255		(228,529	)		865,471
	$	2,013,000	$	(592,864	)	$	1,420,136	$	(392,002	)	$	1,620,998

Goodwill

Property and equipment

	December 31,
	2016			2015
Laboratory and manufacturing equipment	$	3,785,133		$	3,734,044
Office furniture and equipment		688,952			701,557
Computers and network equipment		1,472,144			1,563,177
Leasehold improvements		662,506			659,949
		6,608,735			6,658,727
Less accumulated depreciation		(5,808,012	)		(5,584,017	)
Property and equipment, net	$	800,723		$	1,074,710

Intangible assets and goodwill

Intangible assets and goodwill as of December 31, 2016 were acquired as part of the Merger, and consist of finite-lived intangible assets and goodwill.

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships, and consisted of the following as of December 31, 2016 and 2015:

			December 31, 2016					December 31, 2015
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(67,575	)	$	393,425	$	(21,471	)	$	439,529
Developed technology		458,000		(95,898	)		362,102		(30,474	)		427,526
Customer relationships		1,094,000		(228,529	)		865,471		(72,241	)		1,021,759
	$	2,013,000	$	(392,002	)	$	1,620,998	$	(124,186	)	$	1,888,814

Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During years ended December 31, 2016 and 2015, the Company determined that its finite-lived intangible assets were not impaired.

Goodwill

Deferred rent

Deferred rent is recorded and amortized to the extent the total minimum rental payments allocated to the current period on a straight-line basis exceed or are less than the cash payments required.

Revenue recognition

Revenue from sales of QuickFISH, PNA FISH and XpressFISH diagnostic test products

Revenue is recognized upon shipment to the customer.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

Revenue from license arrangements

The Company recognizes revenue from licenses of its technologies over the applicable license term.

Revenue from sales of the reagents and supplies used for Argus consumable kits

Revenue is recognized for sales of the reagents and supplies used for Argus consumable kits upon shipment to the customer.

The Company recognizes revenue primarily from sales of its products and services when the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred; the selling price is fixed or determinable; and collectability is reasonably assured. At times, the Company sells products and services, or performs software development, under multiple-element arrangements with separate units of accounting; in these situations, total consideration is allocated to the identified units of accounting based on their relative fair value and revenue is then recognized for each unit based on its specific characteristics.

Revenue from sales of QuickFISH, PNA FISH and XpressFISH diagnostic test products

Revenue is recognized upon shipment to the customer.

Revenue from providing laboratory services

The Company recognizes revenue associated with laboratory services contracts when the service has been performed and reports are made available to the customer.

Revenue from funded software development arrangements

Revenue from license arrangements

The Company recognizes revenue from licenses of its technologies over the applicable license term.

Revenue from sales of the Argus System

Revenue from sales of Genome Builder Software and consumables (on a stand-alone basis)

Revenue is recognized for Genome Builder Software and for consumables, when sold on a standalone basis, upon delivery to the customer.

Revenue from extended warranty service contracts

The Company recognizes revenue associated with extended warranty service contracts over the service period in proportion to the costs expected to be incurred over that same period.

Research and development costs

Share-based compensation

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant- date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. A discussion of management's methodology for developing each of the assumptions used in the Black-Scholes model is as follows:

Fair value of common stock

Expected volatility

Expected dividend yield

The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.

Risk-free interest rate

This is the U.S. Treasury rate for the day of each option grant during the year, having a term that most closely resembles the expected term of the option.

Expected term

Income taxes

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted- average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

Recent accounting pronouncements

In July 2015, the FASB issued accounting guidance for inventory. Under the guidance, an entity should measure inventory within the scope of this guidance at the lower of cost and net realizable value, except when inventory is measured using LIFO or the retail inventory method. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. In addition, the FASB has amended some of the other inventory guidance to more clearly articulate the requirements for the measurement and disclosure of inventory. The standard is effective for reporting periods beginning after December 15, 2016. The amendments in this pronouncement should be applied prospectively, with earlier application permitted. The Company is currently evaluating the impact, if any, that this new accounting pronouncement will have on its consolidated financial statements.

Summary of Significant Accounting Policies Basis of Presentation (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Accounting Policies [Abstract]

Schedule of Inventories

	September 30, 2017		December 31, 2016
Raw materials and supplies	$	279,562	$	479,479
Work-in process		40,814		27,422
Finished goods		140,753		185,467
Total	$	461,129	$	692,368

	December 31, 2016		December 31, 2015
Raw materials and supplies	$	479,479	$	362,526
Work-in process		27,422		150,369
Finished goods		185,467		313,117
Total	$	692,368	$	826,012

Property, Plant and Equipment

	December 31,
	2016			2015
Laboratory and manufacturing equipment	$	3,785,133		$	3,734,044
Office furniture and equipment		688,952			701,557
Computers and network equipment		1,472,144			1,563,177
Leasehold improvements		662,506			659,949
		6,608,735			6,658,727
Less accumulated depreciation		(5,808,012	)		(5,584,017	)
Property and equipment, net	$	800,723		$	1,074,710

Schedule of Finite-Lived Intangible Assets

			September 30, 2017					December 31, 2016
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(102,153	)	$	358,847	$	(67,575	)	$	393,425
Developed technology		458,000		(144,966	)		313,034		(95,898	)		362,102
Customer relationships		1,094,000		(345,745	)		748,255		(228,529	)		865,471
	$	2,013,000	$	(592,864	)	$	1,420,136	$	(392,002	)	$	1,620,998

			December 31, 2016					December 31, 2015
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames	$	461,000	$	(67,575	)	$	393,425	$	(21,471	)	$	439,529
Developed technology		458,000		(95,898	)		362,102		(30,474	)		427,526
Customer relationships		1,094,000		(228,529	)		865,471		(72,241	)		1,021,759
	$	2,013,000	$	(392,002	)	$	1,620,998	$	(124,186	)	$	1,888,814

Business Combination (Tables)

12 Months Ended

Dec. 31, 2016

Business Combinations [Abstract]

Schedule of preliminary allocation of the purchase price

Total purchase price – fair value of common stock issued	$	2,584,090
Fair value of tangible assets acquired:
Cash	$	1,367,211
Receivables		536,406
Inventory		881,273
Property and equipment		245,479
Other assets		359,587
Fair value of identifiable intangible assets acquired:
Customer relationships		1,094,000
Developed technology		458,000
Trademarks and tradenames		461,000
Fair value of goodwill		600,814
Deferred tax liabilities, net		129,095
Fair value of liabilities assumed		3,290,585
	$	2,584,090

Schedule of unaudited pro forma financial information

	December 31,
Unaudited pro forma results	2015
Revenues	$	5,231,844
Net loss	$	(20,751,552	)
Net loss per share	$	(63.00	)

Redeemable Convertible Preferred Stock (Tables)

12 Months Ended

Dec. 31, 2016

Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]

Schedule of changes in the Series A Preferred Stock

	Shares			Amount
Balance at December 31, 2014		3,999,864		$	4,564,899
2015 Accretion		—			243,762
2015 Conversions		(3,999,864	)		(4,808,661	)
Balance at December 31, 2015		—		$	—

Stockholders' Equity (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Stockholders' Equity Note [Abstract]

Schedule of allocation of share-based compensation expense

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Cost of services	$	2,306	$	—	$	6,274	$	5,008
Research and development		61,097		45,945		171,652		181,367
General and administrative		187,357		98,683		500,252		447,811
Sales and marketing		16,832		34,124		44,126		72,462
	$	267,592	$	178,752	$	722,304	$	706,648

	Year Ended December 31,
	2016		2015
Cost of services	$	6,003	$	—
Research and development		236,341		240,739
General and administrative		599,550		619,899
Sales and marketing		103,567		584,450
	$	945,461	$	1,445,088

Schedule of share-based compensation, options granted

	Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (in years)		Aggregate Intrinsic Value
Outstanding at January 1, 2015		16,170					9.3	$	—
Granted		78,465			$67.00
Exercised		(458	)		$5.00			$	19,519
Forfeited		(7,746	)		$13.75
Outstanding at December 31, 2015		86,431			$65.00		9.1	$	1,575,646
Granted		58,546			$35.25
Exercised		(2,660	)		$9.00			$	79,406
Forfeited		(22,867	)		$99.75
Expired		(343	)		$212.25
Outstanding at December 31, 2016		119,106			$44.00		8.6	$	663,298
Vested and expected to vest		119,106			$44.00		8.6	$	663,298
Exercisable at December 31, 2016		43,940			$5.50		8.0	$	421,621

Schedule of share-based payment award, Stock Options granted, fair value

	Year Ended December 31,
	2016	2015
Annual dividend	—	—
Expected life (in years)	5.25 – 6.25	5.5 – 6.25
Risk free interest rate	1.2 – 2.2%	1.5 – 1.9%
Expected volatility	42.0 – 49.8%	47.7 – 65.0%

Schedule of warrants to purchase shares of common stock

				Underlying Warrant Shares at
Issuance	Exercise Price		Expiration	September 30, 2017		December 31, 2016
August 2007	$	197.75	August 2017		—		356
March 2008	$	19,763.50	March 2018		1		1
November 2009	$	197.75	November 2019		266		266
January 2010	$	197.75	January 2020		266		266
March 2010	$	197.75	March 2020		51		51
November 2011	$	197.75	November 2021		208		208
December 2011	$	197.75	December 2021		26		26
March 2012	$	109.90	March 2019		165		165
February 2015	$	165.00	February 2025		9,000		9,000
May 2015	$	165.00	May 2020		138,310		138,310
May 2016	$	32.75	May 2021		189,573		189,573
June 2016	$	32.75	May 2021		82,032		82,032
June 2017	$	19,50	June 2022		18,753		—
July 2017	$	17.25	July 2022		6,349		—
July 2017	$	12.50	July 2022		50,000		—
July 2017 (1)	$	0.25	July 2022		113,432		—
July 2017	$	10.75	July 2022		1,000,000		—
					1,608,439		420,260

(1) These July 2017 warrants represent the outstanding pre-funded warrants issued under the July 2017 Public Offering. See Note 7 "Stockholders' equity" and Note 11 "Subsequent events."

				Underlying Warrant Shares at December 31,
Issuance	Exercise Price		Expiration	2016		2015
August 2007	$	197.75	August 2017		356		356
March 2008	$	19,763.50	March 2018		1		1
November 2009	$	197.75	November 2019		266		266
January 2010	$	197.75	January 2020		266		266
March 2010	$	197.75	March 2020		51		51
November 2011	$	197.75	November 2021		208		208
December 2011	$	197.75	December 2021		26		26
March 2012	$	2,747.50	March 2019		165		165
February 2015	$	165.00	February 2025		9,000		9,000
May 2015	$	165.00	May 2020		138,310		138,310
May 2016	$	32.75	May 2021		189,573		—
June 2016	$	32.75	May 2021		82,032		—
					420,260		148,654

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Deferred tax assets and liabilities

	December 31,
	2016			2015
Deferred tax assets:
NOL carryforward	$	60,357,220		$	38,797,762
R&E credit carryforward		2,559,479			1,994,478
Share-based compensation		448,534			383,153
Inventory reserve		269,708			226,299
Depreciation		117,629			313,714
Accruals and other		333,126			495,640
Total deferred tax assets		64,085,696			42,211,046
Valuation allowance		(63,520,548	)		(41,554,045	)
Deferred tax liabilities:
Intangible assets		(565,148	)		(657,001	)
Fixed assets		—			—
Net deferred tax liability	$	—		$	—

Expected income tax provision (benefit) from applying federal statutory tax rates to the pre-tax loss and actual income tax provision (benefit)

	2016			2015
Federal income tax benefit at statutory rates		34.0	%		34.0	%
State income tax benefit, net of Federal benefit		6.5	%		3.3	%
Change in valuation allowance		(37.3	)%		(32.1	)%
Change in state tax rates and other		(3.2	)%		(4.5	)%
		0.0	%		0.7	%

Commitments (Tables)

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Payments For Capital Leases

Year ending December 31,	Capital Leases			Operating Leases		Total
2017	$	204,354		$	1,072,448	$	1,276,802
2018		113,337			1,205,263		1,318,600
2019		21,266			427,769		449,035
2020		21,266			427,769		449,035
2021 and thereafter		1,773			463,416		465,189
Total	$	361,996		$	3,596,665	$	3,958,661
Less: amount representing interest		(31,054	)
Net present value of future minimum lease payments	$	330,942
Current maturities		(184,399	)
Long-term maturities	$	146,543

Schedule of Capital Leased Assets

	2016			2015
Laboratory and manufacturing equipment	$	560,829		$	803,500
Office furniture and equipment		64,790			89,140
Computers and network equipment		24,350			153,693
Less accumulated amortization		(270,808	)		(402,066	)
Capital lease assets, net	$	379,161		$	644,267

Fair Value Measurements (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2017

Dec. 31, 2016

Fair Value Disclosures [Abstract]

Schedule of financial assets and liabilities measured at fair value on a recurring basis

Description

Balance at

December 31,

2016

Established

in 2017

Changes

in Fair

Value

Expensed

Balance at

September 30,

2017

Embedded conversion option liability

—

4,500

—

(4,500

)

—

Warrant liability

—

152,517

(124,139

)

—

28,378

Description

Balance at

December 31,

2014

Established in 2015

Change in Fair Value

Reclassified to Equity

Balance at

December 31,

2015

Derivative warrant liability

—

72,333

647,342

(719,675

)

—

Organization (Details Narrative) - Segments	9 Months Ended	12 Months Ended
Organization (Details Narrative) - Segments	Sep. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating business segment	1	1

Going Concern and Management's Plans (Details Narrative) - USD ($)							1 Months Ended			2 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Mar. 24, 2017	Dec. 31, 2016	Sep. 13, 2016	Jun. 27, 2016	Jul. 14, 2015	Sep. 30, 2016	Jul. 31, 2015	May 31, 2015	Jun. 30, 2016	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	May 08, 2015
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														$ 4,405,973
Net proceeds from sale of common stock												$ 3,426,050	$ 124	4,405,973	$ 17,366,620
Proceeds from initial public offering, net of issuance costs									$ 17,100,000
Merck Ghi Financing Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues						45,454
Net proceeds from sale of common stock						$ 5,000,000
Shares issued, price per share						$ 110.0
Debt instrument, face amount						$ 1,000,000
Debt instrument, carrying amount			$ 1,000,000											1,000,000	1,000,000
At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														440,597,300,000
Private Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														$ 946,074,900,000
Class of warrant or right, number of securities called by warrants or rights					271,606					271,606
Class of warrant or right, exercise price of warrants or rights					$ 1.14					$ 1.14
Sale of stock, description of transaction												(i) one twenty-fifth of share of common stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, at a price of $1.14 per unit.		(i) one share of common stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, at a price of $1.14 per unit.
I P O [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues															1,212,913,300,000
Over Allotment Option [Member]
Conversion of Stock [Line Items]
Class of warrant or right, number of securities called by warrants or rights																3,272,500
Class of warrant or right, exercise price of warrants or rights																$ 6.60
Common Stock [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														$ 1,448	$ 1,000
Stock issued during period, shares, new issues														144,794	100,000
Common Stock [Member] \| Merck Global Health Innovation Fund Llc [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues						45,454		45,454
Net proceeds from sale of common stock						$ 5,000,000
Proceeds from issuance of shares and debt								$ 6,000,000
Shares issued, price per share								$ 110.0
Common Stock [Member] \| At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														$ 3,619,900,000
Stock issued during period, shares, new issues														3,619,863
Common Stock [Member] \| Private Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														$ 6,744,100,000
Stock issued during period, shares, new issues					271,606					269,765				269,765
Common Stock [Member] \| I P O [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues															$ 2,500,000,000
Stock issued during period, shares, new issues															2,500,000
Common Stock [Member] \| Over Allotment Option [Member]
Conversion of Stock [Line Items]
Class of warrant or right, number of securities called by warrants or rights																185,250
Non Voting Convertible Preferred Stock [Member] \| Private Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues					2,309,428					92,377
Additional Paid In Capital [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														$ 4,404,525	$ 12,128,133
Additional Paid In Capital [Member] \| At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														436,977,400,000
Additional Paid In Capital [Member] \| Private Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														937,021,400,000
Additional Paid In Capital [Member] \| I P O [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues															1,210,413,300,000
Preferred Stock [Member] \| At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														0
Preferred Stock [Member] \| Private Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														$ 2,309,400,000
Stock issued during period, shares, new issues														2,309,428
Preferred Stock [Member] \| I P O [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues															0
Retained Earnings [Member] \| At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														$ 0
Retained Earnings [Member] \| Private Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														0
Retained Earnings [Member] \| I P O [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues															0
Accumulated Other Comprehensive Income [Member] \| At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														0
Accumulated Other Comprehensive Income [Member] \| Private Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues														0
Accumulated Other Comprehensive Income [Member] \| I P O [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues															$ 0
Commercial Paper [Member] \| Common Stock [Member] \| Merck Global Health Innovation Fund Llc [Member]
Conversion of Stock [Line Items]
Debt instrument, face amount								$ 1,000,000
Debt instrument, carrying amount			1,000,000											$ 1,000,000
Debt instrument, maturity period														2017-07
Debt instrument, description														If the company is unable to repay the note, negotiate its conversion or extend its term, the assets of the company may be seized, as the note is secured by a lien on all the company’s assets.
Cowen And Company Limited Liability Company [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues							$ 11,500,000
Maximum commission percentage on gross proceeds							3.00%
Net proceeds from sale of common stock	$ 7,800,000											$ 3,400,000
Gross proceeds from sale of common stock	8,400,000											$ 3,600,000
Remaining availability under at the market offering	$ 3,100,000						$ 3,100,000
Cowen And Company Limited Liability Company [Member] \| Scenario Plan [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues				$ 11,500,000
Maximum commission percentage on gross proceeds				3.00%
Net proceeds from sale of common stock			4,400,000											$ 4,400,000
Gross proceeds from sale of common stock			4,700,000											4,700,000
Remaining availability under at the market offering			$ 6,800,000											$ 6,800,000
Cowen And Company Limited Liability Company [Member] \| Scenario Plan [Member] \| Subsequent Event [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Net proceeds from sale of common stock		$ 2,100,000
Gross proceeds from sale of common stock		2,200,000
Remaining availability under at the market offering		$ 4,600,000
Cowen And Company Limited Liability Company [Member] \| Common Stock [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues	308,000										0	160,000
Cowen And Company Limited Liability Company [Member] \| Common Stock [Member] \| Scenario Plan [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues			144,000											36
Cowen And Company Limited Liability Company [Member] \| Common Stock [Member] \| Scenario Plan [Member] \| Subsequent Event [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues		84,000
Maximum [Member] \| Cowen And Company Limited Liability Company [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Aggregate gross proceeds from issuance of common stock							$ 2,500,000,000,000
Maximum [Member] \| Cowen And Company Limited Liability Company [Member] \| Scenario Plan [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Aggregate gross proceeds from issuance of common stock				$ 2,500,000,000,000

Liquidity and Management's Plans (Details Narrative) - USD ($)					1 Months Ended						2 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Jul. 18, 2017	Jun. 06, 2017	Jun. 27, 2016	Jul. 31, 2017	Jun. 28, 2017	Sep. 30, 2016	Jun. 30, 2016	May 31, 2016	Jul. 31, 2015	Jun. 30, 2016	Dec. 31, 2017	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	May 31, 2017
Conversion of Stock [Line Items]
Net proceeds from sale of common stock and warrants														$ 8,754,882	$ 0
Stock issued during period, value, new issues																$ 4,405,973
Net proceeds from sale of common stock														3,426,050	124	4,405,973	$ 17,366,620
Proceeds from issuance of private placement net											$ 9,500,000			$ 0	$ 9,460,751	9,460,749	$ 0
Second Amended And Restated Merck Ghi Financing Agreement [Member]
Conversion of Stock [Line Items]
Interest rate						10.00%
Maturity date														Jul. 14, 2017
Debt instrument, extended maturity date														Jul. 14, 2018
Percentage of warrants to purchase common stock shares on outstanding pricnipal and accrued interest on issuance date						20.00%
Amended And Restated M G H I F Financing Agreement [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights			$ 19.50
Interest rate			10.00%
Class of warrant or right, number of securities called by warrants or rights			13,119
Debt instrument, extended maturity date			Jul. 14, 2018
Warrant expiration period			5 years
M G H I F Financing Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues										45,454
Shares issued, price per share										$ 110.00
Aggregate principal amount										$ 1,000,000
Interest rate										8.00%
Net proceeds from sale of common stock										$ 5,000,000
At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues																$ 440,597,300,000
July Two Thousand Seventeen Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues		18,164,195
Shares issued, price per share		$ 0.40
Gross proceeds from sale of common stock and warrants		$ 1,000,000
Net proceeds from sale of common stock and warrants		$ 8,800,000
Sale of stock, description of transaction														Each unit included one share of common stock and one common warrant to purchase one twenty-fifth of a share of common stock at an exercise price of $10.625 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase one share of common stock at an exercise price of $0.425 per share.
Class of warrant or right, exercise price of warrants or rights		$ 0.425
Warrants exercisable period		5 years
Private Placement [Member]
Conversion of Stock [Line Items]
Sale of stock, description of transaction														(i) one twenty-fifth of share of common stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.03 shares of common stock, at a price of $1.14 per unit.		(i) one share of common stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, or (ii) one share of non-voting convertible preferred stock and a detachable stock purchase warrant to purchase an additional 0.75 shares of common stock, at a price of $1.14 per unit.
Class of warrant or right, exercise price of warrants or rights				$ 1.14				$ 1.14			$ 1.14
Class of warrant or right, number of securities called by warrants or rights				271,606				271,606			271,606
Stock issued during period, value, new issues																$ 946,074,900,000
Proceeds from issuance of private placement net											$ 9,500,000
Common Stock [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																144,794	100,000
Stock issued during period, value, new issues																$ 1,448	$ 1,000
Conversion of stock, shares issued														92,377
Common Stock [Member] \| At The Market Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues																3,619,863
Stock issued during period, value, new issues																$ 3,619,900,000
Common Stock [Member] \| Private Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues				271,606							269,765					269,765
Stock issued during period, value, new issues																$ 6,744,100,000
Prefunded Units [Member] \| July Two Thousand Seventeen Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues		6,835,805
Shares issued, price per share		$ 0.39
Pre Funded Warrant [Member] \| July Two Thousand Seventeen Public Offering [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights		$ 0.01
Warrants exercised		4,000,000			4,000,000
Non Voting Convertible Preferred Stock [Member]
Conversion of Stock [Line Items]
Conversion of stock, shares converted														92,377
Non Voting Convertible Preferred Stock [Member] \| Private Placement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues				2,309,428							92,377
Bridge Financing Notes [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Interest rate																		10.00%
Maturity date														Sep. 30, 2017
Bridge Financing Notes [Member] \| July Two Thousand Seventeen Public Offering [Member]
Conversion of Stock [Line Items]
Repayment of outstanding debt		$ 100,000			$ 100,000
Bridge Financing Notes [Member] \| Warrant [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights					$ 17.25
Class of warrant or right, number of securities called by warrants or rights					6,349
Bridge Financing Notes [Member] \| Stock Purchase Warrants [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights					$ 19.50
Class of warrant or right, number of securities called by warrants or rights					5,633
Bridge Financing Note Three [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Aggregate principal amount																		$ 50,000,000,000
Bridge Financing Note Two [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Aggregate principal amount																		50,000,000,000
Bridge Financing Note One [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Aggregate principal amount																		50,000,000,000
Cowen And Company Limited Liability Company [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, value, new issues							$ 11,500,000
Maximum commission percentage on gross proceeds							3.00%
Net proceeds from sale of common stock	$ 7,800,000													$ 3,400,000
Gross proceeds from sale of common stock	8,400,000													$ 3,600,000
Remaining availability under at the market offering	$ 3,100,000						$ 3,100,000
Cowen And Company Limited Liability Company [Member] \| Common Stock [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues	308,000												0	160,000
Maximum [Member] \| Scenario Forecast [Member]
Conversion of Stock [Line Items]
Expected reduction in operating expenses percentage												30.00%
Maximum [Member] \| Bridge Financing Notes [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Aggregate principal amount																		$ 150,000,000,000
Maximum [Member] \| Cowen And Company Limited Liability Company [Member] \| At The Market Offering [Member] \| Sales Agreement [Member]
Conversion of Stock [Line Items]
Aggregate gross proceeds from issuance of common stock							$ 2,500,000,000,000
Minimum [Member] \| Scenario Forecast [Member]
Conversion of Stock [Line Items]
Expected reduction in operating expenses percentage												25.00%
Minimum [Member] \| Qualified Financing [Member] \| Note Purchase Agreement [Member]
Conversion of Stock [Line Items]
Net proceeds from equity or debt financing														$ 500,000
June2016 Warrant [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights								$ 32.8125			$ 32.8125
Warrant expiration period								5 years
Expiration date of warrants issued								May 18, 2021						May 18, 2021
May2016 Warrant [Member]
Conversion of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights									$ 32.8125
Warrant expiration period									5 years
Expiration date of warrants issued									May 18, 2021					May 18, 2021

Summary of Significant Accounting Policies Basis of Presentation (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Inventories
Raw materials and supplies	$ 279,562	$ 479,479	$ 362,526
Work-in process	40,814	27,422	150,369
Finished goods	140,753	185,467	313,117
Total	$ 461,129	$ 692,368	$ 826,012

Summary of Significant Accounting Policies Basis of Presentation (Details 1) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Significant Accounting Policies [Line Items]
Property and equipment, Gross		$ 6,608,735	$ 6,658,727
Less accumulated depreciation		(5,808,012)	(5,584,017)
Property and equipment, net	$ 750,090	800,723	1,074,710
Laboratory And Manufacturing Equipment [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross		3,785,133	3,734,044
Office Equipment [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross		688,952	701,557
Computer Equipment [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross		1,472,144	1,563,177
Leasehold Improvements [Member]
Significant Accounting Policies [Line Items]
Property and equipment, Gross		$ 662,506	$ 659,949

Summary of Significant Accounting Policies Basis of Presentation (Details 2) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Cost	$ 2,013,000	$ 2,013,000
Accumulated Amortization	(592,864)	(392,002)	$ (124,186)
Net Balance	1,420,136	1,620,998	1,888,814
Trademarks And Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	461,000	461,000
Accumulated Amortization	(102,153)	(67,575)	(21,471)
Net Balance	358,847	393,425	439,529
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	458,000	458,000
Accumulated Amortization	(144,966)	(95,898)	(30,474)
Net Balance	313,034	362,102	427,526
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	1,094,000	1,094,000
Accumulated Amortization	(345,745)	(228,529)	(72,241)
Net Balance	$ 748,255	$ 865,471	$ 1,021,759

Summary of Significant Accounting Policies Basis of Presentation (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Significant Accounting Policies [Line Items]
FDIC limit of insurable cash	$ 250,000	$ 250,000		$ 250,000		$ 250,000
Letters of credit outstanding, amount	243,380	243,380		243,380		243,380	$ 243,380
Allowance for doubtful accounts receivable	26,716	24,783		24,783		26,716	15,596
Inventory valuation reserves	704,516	157,529		157,529		704,516	591,051
Depreciation expense						388,231	500,467
Selling and marketing expense		330,305	$ 1,294,640	2,345,293	$ 4,282,628	5,529,274	4,305,444
Amortization of intangible assets		66,954	66,954	200,862	200,862	267,816	124,186
Finite-lived intangible assets, amortization expense, 2017	268,000					268,000
Finite-lived intangible assets, amortization expense, 2018	268,000					268,000
Finite-lived intangible assets, amortization expense, 2019	268,000					268,000
Finite-lived intangible assets, amortization expense, 2020	268,000					268,000
Finite-lived intangible assets, amortization expense, 2021	$ 268,000					268,000
Impairment of finite-lived intangible assets		$ 0	$ 0	$ 0	$ 0	0	0
Impairment of goodwill						0
Share-based compensation arrangement by share-based payment award, award vesting period	4 years
Operating loss carryforwards	$ 150,950,436					$ 150,950,436	$ 132,359,334
Antidilutive securities excluded from computation of earnings per share, amount				1,800,000	540,000	540,000	240,000
Maximum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due				60 days		60 days
Estimated useful lives of related assets						5 years
Fair value assumptions, expected term						10 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due				30 days		30 days
Estimated useful lives of related assets						3 years
Fair value assumptions, expected term						6 years 3 months
Selling And Marketing Expense [Member]
Significant Accounting Policies [Line Items]
Estimated useful lives of related assets						4 years
Trademarks And Trade Names [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life				10 years		10 years
Developed Technology Rights [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life				7 years		7 years
Customer Relationships [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life				7 years		7 years
Sales Revenue Net [Member] \| Customer Concentration Risk [Member] \| Hitachi High Technologies Corporation [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage						10.00%	11.00%
Sales Revenue Net [Member] \| Customer Concentration Risk [Member] \| Customer One [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			11.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer One [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage					11.00%	25.00%	25.00%
Equipment [Member]
Significant Accounting Policies [Line Items]
Selling and marketing expense						$ 0	$ 175,000

Summary of Significant Accounting Policies Basis of Presentation (Details Narrative 1)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017 USD ($) Customers	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) Segments Customers shares	Sep. 30, 2016 USD ($) Customers shares	Dec. 31, 2016 USD ($) Segments shares	Dec. 31, 2015 USD ($) shares
Significant Accounting Policies [Line Items]
Number of operating business segment \| Segments			1		1
FDIC limit of insurable cash	$ 250,000		$ 250,000		$ 250,000
Letters of credit outstanding, amount	243,380		243,380		243,380	$ 243,380
Allowance for doubtful accounts receivable	$ 24,783		$ 24,783		26,716	15,596
Number of individual customers accounting for more than 10% of revenue \| Customers	0		0	0
Number of individual customers accounting for more than 10% of accounts receivable \| Customers	0		0
Inventory valuation reserves	$ 157,529		$ 157,529		704,516	591,051
Amortization of intangible assets	66,954	$ 66,954	200,862	$ 200,862	267,816	124,186
Finite-lived intangible assets, amortization expense, next twelve months	268,000		268,000
Finite-lived intangible assets, amortization expense, 2019	268,000		268,000
Finite-lived intangible assets, amortization expense, 2020	268,000		268,000
Finite-lived intangible assets, amortization expense, 2021	268,000		268,000
Finite-lived intangible assets, amortization expense, 2022	268,000		268,000
Impairment of finite-lived intangible assets	0	$ 0	0	$ 0	0	0
Goodwill	$ 600,814		$ 600,814		600,814	637,528
Operating loss carryforwards					$ 150,950,436	$ 132,359,334
Antidilutive securities excluded from computation of earnings per share, amount \| shares			1,800,000	540,000	540,000	240,000
Maximum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due			60 days		60 days
Minimum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due			30 days		30 days
Customer Relationships [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			7 years		7 years
Developed Technology Rights [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			7 years		7 years
Trademarks And Trade Names [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			10 years		10 years
Sales Revenue Net [Member] \| Customer Concentration Risk [Member] \| Customer One [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage		11.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer One [Member]
Significant Accounting Policies [Line Items]
Concentration Risk, Percentage				11.00%	25.00%	25.00%

Business Combination (Details) - USD ($)	Jul. 14, 2015	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair value of identifiable intangible assets acquired:
Goodwill		$ 600,814	$ 600,814	$ 637,528
Advandx [Member]
Business Acquisition [Line Items]
Total purchase price - fair value of common stock issued	$ 2,584,090
Fair value of tangible assets acquired:
Cash	1,367,211
Receivables	536,406
Inventory	881,273
Property and equipment	245,479
Other assets	359,587
Fair value of identifiable intangible assets acquired:
Goodwill	600,814		$ 6
Deferred tax liabilities, net	129,095
Fair value of liabilities assumed	3,290,585
Total acquisition purchase price Allocation	2,584,090
Advandx [Member] \| Trademarks And Trade Names [Member]
Fair value of identifiable intangible assets acquired:
Fair value of identifiable intangible assets	461,000
Advandx [Member] \| Developed Technology Rights [Member]
Fair value of identifiable intangible assets acquired:
Fair value of identifiable intangible assets	458,000
Advandx [Member] \| Customer Relationships [Member]
Fair value of identifiable intangible assets acquired:
Fair value of identifiable intangible assets	$ 1,094,000

Business Combination (Details 1)	12 Months Ended
Business Combination (Details 1)	Dec. 31, 2015 USD ($) $ / shares
Business Acquisition, Pro Forma Information [Abstract]
Revenues	$ 5,231,844
Net loss	$ (20,751,552)
Net loss per share \| $ / shares	$ (63.00)

Business Combination (Details Narrative) - USD ($)		3 Months Ended		12 Months Ended
Business Combination (Details Narrative) - USD ($)	Jul. 14, 2015	Mar. 31, 2016	Dec. 31, 2015	Dec. 31, 2016	Sep. 30, 2017
Business Acquisition [Line Items]
Business combination, effective date of acquisition				Jul. 14, 2015
Business combination, percentage of capital stock acquired	100.00%
Deferred tax assets, tax credit carryforwards, foreign	$ 43
Deferred tax liabilities, net, total	$ 1
Goodwill			$ 637,528	$ 600,814	$ 600,814
Goodwill, period increase (decrease), total		$ (36,714)	$ 345,781
Advandx [Member]
Business Acquisition [Line Items]
Business acquisition, equity interest issued or issuable, number of shares	681,818
Equity issued in business combination, fair value disclosure	$ 2,584,090
Goodwill	$ 600,814			$ 6

Merck GHI Financing (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
Merck GHI Financing (Details Narrative) - USD ($)	Jun. 06, 2017	Jul. 31, 2015	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Jun. 28, 2017
Common Stock And Note Purchase Agreement [Line Items]
Proceeds from issuance of common stock, net of issuance costs					$ 3,426,050	$ 124	$ 4,405,973	$ 17,366,620
Adjustments to additional paid in capital, stock issued, issuance costs								$ 58,566
Fair value adjustment of warrants			$ (9,739,500,000)	$ 0	(12,413,900,000)	$ 0
Amended And Restated M G H I F Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, interest rate, stated percentage	10.00%
Debt instrument, extended maturity date	Jul. 14, 2018
Warrant expiration period	5 years
Issuance of common stock warrants to purchase	13,119
Warrants first exercisable period after issuance date	6 months
Class of warrant or right, exercise price of warrants or rights	$ 19.50
Percentage of warrant exercise price on common stock closing price on date of issuance	110.00%
Estimated fair value of debt			$ 1,000,000		1,000,000		$ 1,000,000
Amended And Restated M G H I F Financing Agreement [Member] \| Black Scholes Model [Member]
Common Stock And Note Purchase Agreement [Line Items]
Fair value adjustment of warrants					$ 100,000
M G H I F Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues		45,454
Shares issued, price per share		$ 110.00
Proceeds from issuance of common stock, net of issuance costs		$ 5,000,000
Debt instrument, interest rate, stated percentage		8.00%
Debt instrument, face amount		$ 1,000,000
Fees related to common stock and debt transaction		5,000,000,000
Deferred debt issuance costs		800,000,000
Adjustments to additional paid in capital, stock issued, issuance costs		$ 4,200,000,000
Second Amended And Restated Merck Ghi Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, interest rate, stated percentage									10.00%
Debt instrument, extended maturity date					Jul. 14, 2018

Redeemable Convertible Preferred Stock (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Conversions	$ 0	$ 7,804,172
Series A Preferred Stock [Member]
Balance (in shares)	0	3,999,864
Balance	$ 0	$ 4,564,899
Accretion		$ 243,762
Conversions (In shares)		(3,999,864)
Conversions		$ (4,808,661)
Balance (In shares)		0
Balance		$ 0

Redeemable Convertible Preferred Stock (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Apr. 30, 2014	Feb. 28, 2014	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	May 08, 2015
Class of Stock [Line Items]
Debt conversion, original debt, amount				$ 0	$ 3,000,000
Common Stock
Class of Stock [Line Items]
Convertible preferred stock, shares issued upon conversion					294,994		294,994
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity redemption request of minimum percentage of holders of outstanding preferred stock required					70.00%
Temporary equity, shares issued	594,904	1,405,096	1,999,864
Temporary equity, par or stated value per share			$ 1.00
Debt conversion, original debt, amount			$ 1,999,864
Proceeds from Issuance of convertible preferred stock	$ 594,904	$ 1,405,096
Payment of financing and stock issuance costs, total						$ 62,098
Preferred stock, dividend rate, percentage					8.00%
Conversion rate description				The initial conversion rate was one common share for each preferred share, which may be adjusted for specified dilutive transactions.

Debt (Details Narrative)		1 Months Ended	2 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
Debt (Details Narrative)	May 08, 2015 USD ($) shares	May 31, 2015 USD ($)	Mar. 31, 2015 USD ($) $ / shares	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) shares	Dec. 31, 2014 shares	Jun. 30, 2016 shares	Jun. 27, 2016 shares	Jul. 14, 2015
Debt Instrument [Line Items]
Proceeds from notes payable							$ 0	$ 204,895	$ 204,895	$ 1,741,667
Debt conversion, converted instrument, amount									0	2,100,000
Interest expense, debt				$ 90,317	$ 41,423		173,974	109,806	143,347	1,801,320
Amortization of financing costs		$ 7,142,100,000
Fair value adjustment of warrants				$ (9,739,500,000)	$ 0		$ (12,413,900,000)	$ 0
Merck Ghi Financing Agreement [Member]
Debt Instrument [Line Items]
Long-term debt, gross									1,000,000	$ 1,000,000
Debt instrument, interest rate, stated percentage														8.00%
I P O [Member]
Debt Instrument [Line Items]
Debt conversion, converted instrument, shares issued \| shares	350,000
Common stock percent										110.00%
Private Placement [Member]
Debt Instrument [Line Items]
Class of warrant or right, number of securities called by warrants or rights \| shares												271,606	271,606
Over Allotment Option [Member]
Debt Instrument [Line Items]
Class of warrant or right, number of securities called by warrants or rights \| shares	3,272,500
Common Stock [Member] \| Over Allotment Option [Member]
Debt Instrument [Line Items]
Class of warrant or right, number of securities called by warrants or rights \| shares	185,250
Loans Payable [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage										8.00%
Commercial Paper [Member] \| Common Stock [Member] \| Merck Global Health Innovation Fund Llc [Member]
Debt Instrument [Line Items]
Long-term debt, gross									$ 1,000,000
Convertible Notes2015 [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage			8.00%
Proceeds from other short-term debt			$ 1,500,000
Fair value adjustment of warrants	$ 700,000
Convertible Notes2015 [Member] \| I P O [Member]
Debt Instrument [Line Items]
Debt conversion, converted instrument, shares issued \| shares										75,000
Convertible Notes2015 [Member] \| Before Closing Ipo [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion ratio			1.25
Convertible Notes2015 [Member] \| After Closing Ipo [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion ratio			1.00
Convertible Notes2015 [Member] \| Common Stock [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price \| $ / shares			$ 1.00
Class of warrant or right, number of securities called by warrants or rights \| shares										9,000
Demand Notes Payable [Member]
Debt Instrument [Line Items]
Debt conversion, converted instrument, amount	$ 2,100,000
Convertible Notes2014 [Member]
Debt Instrument [Line Items]
Proceeds from convertible debt						$ 1,500,000
Convertible Notes2014 [Member] \| I P O [Member]
Debt Instrument [Line Items]
Debt conversion, converted instrument, shares issued \| shares											60,000

Debt (Details Narrative 1)	2 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
Debt (Details Narrative 1)	Jul. 31, 2017 Notes	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) Notes	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Debt Instrument [Line Items]
Short-term debt		$ 1,100,012		$ 1,100,012		$ 1,023,815	$ 0
Interest expense, debt		90,317	$ 41,423	173,974	$ 109,806	143,347	$ 1,801,320
M G H I F Financing Agreement [Member]
Debt Instrument [Line Items]
Short-term debt		1,000,000		$ 1,000,000
Long-term debt, outstanding						$ 1,000,000
Bridge Financing Notes [Member]
Debt Instrument [Line Items]
Number of notes \| Notes				3
Number of notes drew down \| Notes	2
Notes Payable Other Payables [Member]
Debt Instrument [Line Items]
Short-term debt		200,000		$ 200,000
Due In Two Thousand Eighteen [Member]
Debt Instrument [Line Items]
Debt instrument, annual principal payment		1,000,000		1,000,000
Due In Two Thousand Seventeen [Member]
Debt Instrument [Line Items]
Debt instrument, annual principal payment		$ 200,000		$ 200,000

Stockholders' Equity (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Stockholders' Equity (Details) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 267,592	$ 178,752	$ 722,304	$ 706,648	$ 945,461	$ 1,445,088
Cost Of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	2,306	0	6,274	5,008	6,003	0
Research And Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	61,097	45,945	171,652	181,367	236,341	240,739
General And Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	187,357	98,683	500,252	447,811	599,550	619,899
Selling And Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 16,832	$ 34,124	$ 44,126	$ 72,462	$ 103,567	$ 584,450

Stockholders' Equity (Details 1) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
Stockholders' Equity (Details 1) - USD ($)	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Number of Options, Outstanding Balance		119,106	86,431	16,170
Number of Options, Granted	16,380	51,164	58,546	78,465
Number of Options, Exercised			(2,660)	(458)
Number of Options, Forfeited	(7,851)	(20,167)	(22,867)	(7,746)
Number of Options, Expired			(343)
Number of Options, Outstanding Balance			119,106	86,431	16,170
Number of Options, Vested and expected to vest			119,106
Number of Options, Exercisable			43,940
Weighted Average Exercise Price, Outstanding Balance		$ 44.00	$ 65.00	$ 0.00
Weighted Average Exercise Price, Granted	$ 7.50	19.00	35.25	67.00
Weighted Average Exercise Price, Exercised			9.00	5.00
Weighted Average Exercise Price, Forfeited	$ 27.75	$ 33.25	99.75	13.75
Weighted Average Exercise Price, Expired			212.25
Weighted Average Exercise Price, Outstanding Balance			44.00	$ 65.00	$ 0.00
Weighted Average Exercise Price, Vested and expected to vest			44.00
Weighted Average Exercise Price, Exercisable			$ 5.50
Weighted-Average Remaining Contractual Life, Outstanding (in years)			8 years 7 months 6 days	9 years 1 month 6 days	9 years 3 months 18 days
Weighted-Average Remaining Contractual Life, Vested and expected to vest (in years)			8 years 7 months 6 days
Weighted-Average Remaining Contractual Life, Exercisable (in years)			8 years
Aggregate Intrinsic Value, Outstanding		$ 663,298	$ 1,575,646	$ 0
Aggregate Intrinsic Value, Exercised			79,406	19,519
Aggregate Intrinsic Value, Outstanding			663,298	$ 1,575,646	$ 0
Aggregate Intrinsic Value, Vested and expected to vest			663,298
Aggregate Intrinsic Value, Exercisable			$ 421,621

Stockholders' Equity (Details 2)	12 Months Ended
Stockholders' Equity (Details 2)	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual dividend	0.00%	0.00%
Risk free interest rate, minimum	1.20%	1.50%
Risk free interest rate, maximum	2.20%	1.90%
Expected volatility, minimum	42.00%	47.70%
Expected volatility, maximum	49.80%	65.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	5 years 3 months	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	6 years 3 months	6 years 3 months

Stockholders' Equity (Details 3) - $ / shares	9 Months Ended	12 Months Ended
Stockholders' Equity (Details 3) - $ / shares	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of Common Stock Subject to Warrants	40,210,978	10,506,524	3,716,355
August Two Thousand Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2017-08	2017-08
Shares of Common Stock Subject to Warrants		8,921	8,921
March Two Thousand Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 790.54	$ 790.54
Expiration	2018-03	2018-03
Shares of Common Stock Subject to Warrants	46	46	46
November Two Thousand Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2019-11	2019-11
Shares of Common Stock Subject to Warrants	6,674	6,674	6,674
January Two Thousand Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2020-01	2020-01
Shares of Common Stock Subject to Warrants	6,674	6,674	6,674
March Two Thousand Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2020-03	2020-03
Shares of Common Stock Subject to Warrants	1,277	1,277	1,277
November Two Thousand Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2021-11	2021-11
Shares of Common Stock Subject to Warrants	5,213	5,213	5,213
December Two Thousand Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2021-12	2021-12
Shares of Common Stock Subject to Warrants	664	664	664
March Two Thousand Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 109.90	$ 109.90
Expiration	2019-03	2019-03
Shares of Common Stock Subject to Warrants	4,125	4,125	4,125
February Two Thousand Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 6.60	$ 6.60
Expiration	2025-02	2025-02
Shares of Common Stock Subject to Warrants	225,011	225,011	225,011
May Two Thousand Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 6.60	$ 6.60
Expiration	2020-05	2020-05
Shares of Common Stock Subject to Warrants	3,457,750	3,457,750	3,457,750
May Two Thousand Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.31	$ 1.31
Expiration	2021-05	2021-05
Shares of Common Stock Subject to Warrants	4,739,348	4,739,348	0
June Two Thousand Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.31	$ 1.31
Expiration	2021-05	2021-05
Shares of Common Stock Subject to Warrants	2,050,821	2,050,821	0

Stockholders' Equity (Details 4) - $ / shares	9 Months Ended	12 Months Ended
Stockholders' Equity (Details 4) - $ / shares	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of Common Stock Subject to Warrants	40,210,978	10,506,524	3,716,355
August Two Thousand Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2017-08	2017-08
Shares of Common Stock Subject to Warrants		8,921	8,921
March Two Thousand Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 790.54	$ 790.54
Expiration	2018-03	2018-03
Shares of Common Stock Subject to Warrants	46	46	46
November Two Thousand Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2019-11	2019-11
Shares of Common Stock Subject to Warrants	6,674	6,674	6,674
January Two Thousand Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2020-01	2020-01
Shares of Common Stock Subject to Warrants	6,674	6,674	6,674
March Two Thousand Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2020-03	2020-03
Shares of Common Stock Subject to Warrants	1,277	1,277	1,277
November Two Thousand Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2021-11	2021-11
Shares of Common Stock Subject to Warrants	5,213	5,213	5,213
December Two Thousand Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 7.91	$ 7.91
Expiration	2021-12	2021-12
Shares of Common Stock Subject to Warrants	664	664	664
March Two Thousand Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 109.90	$ 109.90
Expiration	2019-03	2019-03
Shares of Common Stock Subject to Warrants	4,125	4,125	4,125
February Two Thousand Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 6.60	$ 6.60
Expiration	2025-02	2025-02
Shares of Common Stock Subject to Warrants	225,011	225,011	225,011
May Two Thousand Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 6.60	$ 6.60
Expiration	2020-05	2020-05
Shares of Common Stock Subject to Warrants	3,457,750	3,457,750	3,457,750
May Two Thousand Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.31	$ 1.31
Expiration	2021-05	2021-05
Shares of Common Stock Subject to Warrants	4,739,348	4,739,348	0
June Two Thousand Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 1.31	$ 1.31
Expiration	2021-05	2021-05
Shares of Common Stock Subject to Warrants	2,050,821	2,050,821	0
June Two Thousand Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.78
Expiration	2022-06
Shares of Common Stock Subject to Warrants	468,840
July Two Thousand Seventeen [Member] \| Warrants Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.69
Expiration	2022-07
Shares of Common Stock Subject to Warrants	158,730
July Two Thousand Seventeen [Member] \| Warrants Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.50
Expiration	2022-07
Shares of Common Stock Subject to Warrants	1,250,000
July Two Thousand Seventeen [Member] \| Warrants Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.01
Expiration	2022-07
Shares of Common Stock Subject to Warrants	2,835,805
July Two Thousand Seventeen [Member] \| Warrants Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 0.43
Expiration	2022-07
Shares of Common Stock Subject to Warrants	25,000,000

Stockholders' Equity (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	May 08, 2015	Jul. 31, 2016	Sep. 30, 2017	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Jan. 17, 2018
Stockholders' Equity Note [Abstract]
Common stock, shares authorized			200,000,000	200,000,000	200,000,000	200,000,000	50,000,000
Common stock, shares issued			2,078,595	2,078,595	1,012,170	501,907
Common stock, shares outstanding			2,078,595	2,078,595	1,012,170	501,907
Preferred stock, shares authorized			10,000,000	10,000,000	10,000,000	10,000,000
Preferred stock, shares issued			0	0	0	0
Preferred stock, shares outstanding			0	0	0	0
Convertible preferred stock, beneficial conversion feature recognized as deemed dividend		$ 332,550		$ 332,550
Proceeds from issuance of units under initial public offering gross	$ 171
Proceeds from issuance of units under initial public offering net	$ 121
Stock and warrants issued during period shares initial public offering purchase price per unit	$ 6.00
Share-based compensation, tax benefit from compensation expense				$ 0	$ 0
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, total					$ 22
Employee service share-based compensation, non-vested awards, compensation cost not yet recognized, period for recognition					1 year 2 months 1 day
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value					$ 1,088,978	$ 1,140,079
Share-based compensation arrangement by share-based payment award, options, grants in period, gross			16,380	51,164	58,546	78,465

Stockholders' Equity (Details Narrative 1) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
Stockholders' Equity (Details Narrative 1) - USD ($)	Jul. 31, 2016	Jun. 30, 2016	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Jan. 17, 2018
Stockholders' Equity Note [Abstract]
Common stock, shares authorized			200,000,000	200,000,000		200,000,000	200,000,000	50,000,000
Common stock, shares issued			2,078,595	2,078,595		1,012,170	501,907
Common stock, shares outstanding			2,078,595	2,078,595		1,012,170	501,907
Preferred stock, shares authorized			10,000,000	10,000,000		10,000,000	10,000,000
Preferred stock, shares issued			0	0		0	0
Preferred stock, shares outstanding			0	0		0	0
Net proceeds from sale of common stock and warrants				$ 8,754,882	$ 0
Proceeds from issuance of common stock, net of issuance costs				3,426,050	124	$ 4,405,973	$ 17,366,620
Proceeds from issuance of private placement net		$ 9,500,000		0	$ 9,460,751	$ 9,460,749	$ 0
Convertible preferred stock, beneficial conversion feature recognized as deemed dividend	$ 332,550			$ 332,550
Share-based compensation arrangement by share-based payment award, options, grants in period, gross			16,380	51,164		58,546	78,465
Share-based compensation, tax benefit from compensation expense				$ 0		$ 0
Share-based compensation arrangements by share-based payment award, options, grants in Period, weighted average exercise price			$ 7.50	$ 19.00		$ 35.25	$ 67.00
Share-based compensation arrangement by share-based payment award, options, forfeitures in period			7,851	20,167		22,867	7,746
Share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price			$ 27.75	$ 33.25		$ 99.75	$ 13.75

Income Taxes (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
NOL carryforward	$ 60,357,220	$ 38,797,762
R&E credit carryforward	2,559,479	1,994,478
Share-based compensation	448,534	383,153
Inventory reserve	269,708	226,299
Depreciation	117,629	313,714
Accruals and other	333,126	495,640
Total deferred tax assets	64,085,696	42,211,046
Valuation allowance	(63,520,548)	(41,554,045)
Deferred tax liabilities:
Intangible assets	(565,148)	(657,001)
Fixed assets	0	0
Net deferred tax liability	$ 0	$ 0

Income Taxes (Details 1)	12 Months Ended
Income Taxes (Details 1)	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Federal income tax benefit at statutory rates	34.00%	34.00%
State income tax benefit, net of Federal benefit	6.50%	3.30%
Change in valuation allowance	(37.30%)	(32.10%)
Change in state tax rates and other	(3.20%)	(4.50%)
Total	0.00%	0.70%

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Tax [Line Items]
Deferred tax assets, net of valuation allowance, total	$ 63,520,548	$ 41,554,045
Deferred tax assets, valuation allowance	63,520,548	41,554,045
Operating loss carryforwards	150,950,436	132,359,334
Domestic Country [Member]
Income Tax [Line Items]
Operating loss carryforwards	$ 150,950,436	$ 132,359,334
Operating loss carry forwards, expiration terms	begin to expire in 2022.

Commitments (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Capital Leases
2017		$ 204,354
2018		113,337
2019		21,266
2020		21,266
2021 and thereafter		1,773
Total		361,996
Less: amount representing interest		(31,054)
Net present value of future minimum lease payments		330,942
Current maturities	$ (160,485)	(184,399)	$ (251,800)
Long-term maturities		146,543
Operating Leases
2017		1,072,448
2018		1,205,263
2019		427,769
2020		427,769
2021 and thereafter		463,416
Total		3,596,665
Total
2017		1,276,802
2018		1,318,600
2019		449,035
2020		449,035
2021 and thereafter		465,189
Total		$ 3,958,661

Commitments (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Loss Contingencies [Line Items]
Less accumulated amortization	$ (270,808)	$ (402,066)
Capital lease assets, net	379,161	644,267
Equipment [Member]
Loss Contingencies [Line Items]
Capital leased assets gross	560,829	803,500
Furniture And Fixtures [Member]
Loss Contingencies [Line Items]
Capital leased assets gross	64,790	89,140
Computer Equipment [Member]
Loss Contingencies [Line Items]
Capital leased assets gross	$ 24,350	$ 153,693

Commitments (Details Narrative) - USD ($)	3 Months Ended					9 Months Ended		12 Months Ended
Commitments (Details Narrative) - USD ($)	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Other Commitments [Line Items]
Operating lease description		The Company leases a facility in Woburn, Massachusetts under an operating lease that expires January 30, 2022. The Company also leases a facility in Gaithersburg, Maryland under an operating lease that expires January 31, 2021, with one additional five-year renewal at the Company’s election. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis.				The Company leases a facility in Woburn, Massachusetts under an operating lease that expires January 30, 2022. The Company also leases a facility in Gaithersburg, Maryland under an operating lease that expires January 31, 2021, with one additional five-year renewal at the Company’s election. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis.		During the second quarter of 2015, the Company extended the term of its Gaithersburg, Maryland office lease, effective May 7, 2015, through January 31, 2021, with one additional five-year renewal at the Company’s election. The Company is responsible for all utilities, repairs, insurance, and taxes under this operating lease. Effective July 1, 2015, the Company further modified its lease agreement to add additional leased space to its headquarters. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis.
Operating leases, rent expense, net, total	$ 238,791	$ 232,836	$ 254,219	$ 254,044		$ 710,330	$ 756,608	$ 1,000,726	$ 683,519
Capital leases description		The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2021. The leases require monthly principal and interest payments.				The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2021. The leases require monthly principal and interest payments.		The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2021. The leases require monthly principal and interest payments.
Capital leases expiration date description		The leases expire at various dates through 2021.				The leases expire at various dates through 2021.		The leases expire at various dates through 2021.
MARYLAND
Other Commitments [Line Items]
Operating leases expiration date						Jan. 31, 2021		Jan. 31, 2021
Operating leases additional term					5 years	5 years
MASSACHUSETTS \| Advandx [Member]
Other Commitments [Line Items]
Operating leases expiration date		Jan. 30, 2022				Jan. 30, 2022		Jan. 30, 2022
MARYLAND
Other Commitments [Line Items]
Operating leases expiration date		Jan. 31, 2021
Operating leases additional term		5 years
Capital Lease Obligations [Member]
Other Commitments [Line Items]
Capital leases, income statement, amortization expense								$ 161,606	$ 157,036

Commitments (Details Narrative 1) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
Commitments (Details Narrative 1) - USD ($)	Dec. 31, 2017	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Mar. 31, 2016	Jun. 30, 2015	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Other Commitments [Line Items]
Operating lease description			The Company leases a facility in Woburn, Massachusetts under an operating lease that expires January 30, 2022. The Company also leases a facility in Gaithersburg, Maryland under an operating lease that expires January 31, 2021, with one additional five-year renewal at the Company’s election. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis.				The Company leases a facility in Woburn, Massachusetts under an operating lease that expires January 30, 2022. The Company also leases a facility in Gaithersburg, Maryland under an operating lease that expires January 31, 2021, with one additional five-year renewal at the Company’s election. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis.		During the second quarter of 2015, the Company extended the term of its Gaithersburg, Maryland office lease, effective May 7, 2015, through January 31, 2021, with one additional five-year renewal at the Company’s election. The Company is responsible for all utilities, repairs, insurance, and taxes under this operating lease. Effective July 1, 2015, the Company further modified its lease agreement to add additional leased space to its headquarters. Additionally, the Company leases office space in Denmark; this lease is currently on a month-to-month basis.
Operating leases, rent expense, net, total		$ 238,791	$ 232,836	$ 254,219	$ 254,044		$ 710,330	$ 756,608	$ 1,000,726	$ 683,519
Capital leases description			The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2021. The leases require monthly principal and interest payments.				The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2021. The leases require monthly principal and interest payments.		The Company leases computer equipment, office furniture, and equipment under various capital leases. The leases expire at various dates through 2021. The leases require monthly principal and interest payments.
Capital leases expiration date description			The leases expire at various dates through 2021.				The leases expire at various dates through 2021.		The leases expire at various dates through 2021.
Restructuring benefits recognized		0					$ 121,000
Expected retention expense							68,000
Retention expense incurred		34,000					$ 47,000
Future minimum operating lease payments									$ 3,596,665
Designated service period of employees, description							The service periods end in December 2017
stpr:MD
Other Commitments [Line Items]
Operating leases expiration date							Jan. 31, 2021		Jan. 31, 2021
Operating leases additional term						5 years	5 years
MOROCCO
Other Commitments [Line Items]
Future minimum operating lease payments		$ 18					$ 18
MOROCCO \| Advandx [Member]
Other Commitments [Line Items]
Operating leases expiration date			Jan. 30, 2022				Jan. 30, 2022		Jan. 30, 2022
Maximum [Member] \| Scenario Forecast [Member]
Other Commitments [Line Items]
Expected reduction in operating expenses percentage	30.00%
Minimum [Member] \| Scenario Forecast [Member]
Other Commitments [Line Items]
Expected reduction in operating expenses percentage	25.00%

License Agreements, Research Collaborations and Development Agreements (Details Narrative)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017 USD ($) Agreements	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) Agreements	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) Agreements	Dec. 31, 2015 USD ($)
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of license agreements \| Agreements					5
Royalty expense	$ 62,500	$ 71,135	$ 194,686	$ 216,937	$ 290,491	$ 205,147
Annual future minimum royalty payments due	250,000		250,000		250,000
Collaborations revenue	6,302	$ 6,302	33,699	$ 131,302	272,603	336,102
Collaborative Arrangement Technology Development Agreement [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Collaborations revenue					0	$ 336,102
Collaborative Arrangement License Agreement [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Collaborations revenue	$ 6,301		$ 18,698		$ 137,603
F I S H Product Line [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of license agreements \| Agreements	1		1		2
Argus And Map It Product Lines [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of license agreements \| Agreements					3

License Agreements, Research Collaborations and Development Agreements (Details Narrative 1)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017 USD ($) Agreements	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) Agreements	Sep. 30, 2016 USD ($)	Dec. 31, 2016 USD ($) Agreements	Dec. 31, 2015 USD ($)
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of license agreements \| Agreements					5
Royalty expense	$ 62,500	$ 71,135	$ 194,686	$ 216,937	$ 290,491	$ 205,147
Annual future minimum royalty payments due	250,000		250,000		250,000
Collaborations revenue	6,302	$ 6,302	33,699	$ 131,302	272,603	$ 336,102
Collaborative Arrangement License Agreement [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Collaborations revenue	$ 6,301		$ 18,698		$ 137,603
F I S H Product Line [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of license agreements \| Agreements	1		1		2

Related Party Transactions (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended		11 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Oct. 31, 2016
Merck Sharp And Dohme Corp [Member]
Related Party Transaction [Line Items]
Research and development agreement description					Under the agreement, Merck provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. Merck gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs.			Under the agreement, Merck will provide access to its archive of over 200,000 bacterial pathogens. OpGen will initially perform molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of OpGen’s rapid diagnostic products. Merck will gain access to the high-resolution genotype data for the isolates as well as access to OpGen’s Acuitas Lighthouse informatics to support internal research and development programs.
Maximum required amount to expend for procurement of materials										$ 175,000
Healthcare Services And Solutions Llc [Member]
Related Party Transaction [Line Items]
Related party transaction, maximum amount of agreement		$ 150,000
Related party transaction, amount recognized	$ 135,000	135,000						$ 135,000
Supply Agreement [Member]
Related Party Transaction [Line Items]
Contractual agreement period					5 years			5 years
Additional contractual agreement period					5 years			5 years
Contractual agreement maturity date					Mar. 17, 2018			Mar. 17, 2018
Contractual agreement description					The initial term of the Fluidigm Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term was extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms.			The initial term of the Fluidigm Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term was extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms.
Related party transaction, expenses from transactions with related party			$ 30,200	$ 0	$ 74,921	$ 160,089		$ 183,713	$ 295,442
Related party transaction, purchases from related party			19,760	23,624	110,239	91,399		91,399	370,539
Payments to acquire equipment on lease			15,683	$ 45,106	76,199	$ 135,319		175,475	$ 119,919
Research And Development Expense [Member] \| Merck Sharp And Dohme Corp [Member]
Related Party Transaction [Line Items]
Procurement costs recognized			$ 0		$ 113,907		$ 146,177	$ 32,270
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer One [Member]
Related Party Transaction [Line Items]
Concentration risk, percentage						11.00%		25.00%	25.00%
Accounts Receivable [Member] \| Customer Concentration Risk [Member] \| Customer One [Member] \| Healthcare Services And Solutions Llc [Member]
Related Party Transaction [Line Items]
Concentration risk, percentage	25.00%
Accounts receivable from related party	$ 135,000	$ 135,000						$ 135,000
Sales Revenue Net [Member] \| Customer Concentration Risk [Member] \| Customer One [Member]
Related Party Transaction [Line Items]
Concentration risk, percentage				11.00%
Sales Revenue Net [Member] \| Customer Concentration Risk [Member] \| Hitachi High Technologies Corporation [Member]
Related Party Transaction [Line Items]
Concentration risk, percentage								10.00%	11.00%

Related Party Transactions (Details Narrative 1) - USD ($)	3 Months Ended		9 Months Ended		11 Months Ended	12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Oct. 31, 2016
Merck Sharp And Dohme Corp [Member]
Related Party Transaction [Line Items]
Research and development agreement description			Under the agreement, Merck provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. Merck gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs.			Under the agreement, Merck will provide access to its archive of over 200,000 bacterial pathogens. OpGen will initially perform molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of OpGen’s rapid diagnostic products. Merck will gain access to the high-resolution genotype data for the isolates as well as access to OpGen’s Acuitas Lighthouse informatics to support internal research and development programs.
Maximum required amount to expend for procurement of materials								$ 175,000
Supply Agreement [Member]
Related Party Transaction [Line Items]
Contractual agreement period			5 years			5 years
Additional contractual agreement period			5 years			5 years
Contractual agreement maturity date			Mar. 17, 2018			Mar. 17, 2018
Contractual agreement description			The initial term of the Fluidigm Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term was extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms.			The initial term of the Fluidigm Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term was extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms.
Related party transaction, expenses from transactions with related party	$ 30,200	$ 0	$ 74,921	$ 160,089		$ 183,713	$ 295,442
Related party transaction, purchases from related party	19,760	23,624	110,239	91,399		91,399	370,539
Payments to acquire equipment on lease	15,683	$ 45,106	76,199	$ 135,319		175,475	$ 119,919
Research And Development Expense [Member] \| Merck Sharp And Dohme Corp [Member]
Related Party Transaction [Line Items]
Procurement costs recognized	$ 0		$ 113,907		$ 146,177	$ 32,270

Fair Value Measurements (Details) - USD ($)	9 Months Ended	12 Months Ended
Fair Value Measurements (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2015
Embedded Conversion Option Liability [Member]
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the beginning of the period	$ 0
Established in 2017/2015	4,500
Expensed/Reclassified	(4,500)
Balance at the end of the period	0
Warrant [Member]
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the beginning of the period	0	$ 0
Established in 2017/2015	152,517	72,333
Changes in Fair Value	(124,139)	647,342
Expensed/Reclassified	0	(719,675)
Balance at the end of the period	$ 28,378	$ 0

Fair Value Measurements (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Fair Value Measurements (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets transferred between fair value measurement levels			$ 0
Fair Value Measurements Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets measured at fair value	$ 0		0
Financial liabilities measured at fair value	0		0
Impairment of non-financial assets and liabilities at fair value	0	$ 0	0	$ 0
Fair Value Measurements Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-financial assets measured at fair value	0		0
Non-financial liabilities measured at fair value	$ 0		$ 0

Subsequent Events (Details Narrative) - shares	1 Months Ended
Subsequent Events (Details Narrative) - shares	Jan. 17, 2018	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Subsequent Events Details Narrative
Stock split	On January 17, 2018, the Board of Directors of the Company approved a one-for-twenty-five reverse stock split. All share and per share information in these consolidated financial statements, except for par value and authorized shares, have been amended to reflect the reverse stock split.
Common stock authorized	50,000,000	200,000,000	200,000,000	200,000,000

Subsequent Events (Details Narrative 1) - Pre Funded Warrant [Member] - July Two Thousand Seventeen Public Offering [Member] - shares		1 Months Ended
	Jul. 18, 2017	Oct. 16, 2017	Jul. 31, 2017
Subsequent Event [Line Items]
Warrants exercised	4,000,000		4,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Warrants exercised		6,835,805